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Abstract 
Short chain fatty acids (SCFAs), generated from the microbial fermentation of dietary fibers, alter 
lipid metabolism. However, sex-specific effects of SCFAs on lipid metabolism and lipidomic 
profiles are not known. Male and female Long-Evans rats were either given a mixture of SCFAs 
(acetate, propionate, and butyrate; molar ratio 60:20:20), or vehicle for seven days 
intraperitoneally. SCFAs significantly decreased plasma and hepatic cholesterol, triacylglycerols 
and plasma glucose in males, while there was no effect in females compared to their respective 
controls. SCFAs showed a significant decrease in the mRNA expression of acetyl-CoA 
carboxylase in both males and females. SCFAs also altered the lipidomic profile of cholesteryl 
esters, triacylglycerols and phospholipids by decreasing the abundance of saturates and 
monounsaturates with a relative increase in polyunsaturated fatty acids. These findings 
demonstrate that SCFAs improve plasma and hepatic lipid profiles in a sex-specific manner, and 
may represent a cheaper therapeutic strategy against metabolic diseases. 
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1.1 Gut microbiota 
1.1.1. Colonic composition of bacteria 
 
The human gastrointestinal tract houses approximately 100 trillion microbes, known as the 
gut microbiome (Whitman, Coleman, and Wiebe 1998; Clemente et al. 2012; Boulangé et al. 
2016). Bacteria are the most dominant and most diverse group, which comprises about 1014 
colonies with more than 70 genera and 500-1000 different species (den Besten et al. 2013). A 
balanced and diversified microbiota is of utmost importance, as microbial composition leads to 
gut dysbiosis – a condition which causes obesity, inflammation, atherosclerosis, type 2 diabetes 
(T2D) or even cancer (Conlon and Bird 2015; Boulangé et al. 2016). These bacterial groups can 
be beneficial or harmful to the body, depending on the metabolites produced by them during 
fermentation (Conlon and Bird 2015). Following  fermentation of complex carbohydrates (such as 
dietary fibers), the gut microbiota produce short chain fatty acids (SCFAs) as main metabolites ( 
Topping and Clifton 2001; Mudgil and Barak 2013; David et al. 2014). SCFAs are of 2-6 carbons 
in length, and are known by the following names: acetic (C2), propionic (C3), butyric (C4), valeric 
(C5) and caproic (C6) acid. Of all, acetate, propionate and butyrate are considered as the three 
main SCFAs. Under symbiotic conditions, SCFAs are generated in the molar ratio of 60:20:20 in 
the colon (Cummings et al. 1987; Hijova and Chmelarova 2007; Ohira, Tsutsui, and Fujioka 2017).  
 
Bacteroidetes, Firmicutes, and Actinobacteria are three of the most abundant phyla present 
in gut microbiota (den Besten et al. 2013). The proximal colon comprises of saccharolytic bacteria 
which belong to Bacteroidetes and Firmicutes phyla, and are responsible mainly for acetate, 
propionate and butyrate production in gut (Topping and Clifton 2001) whereas, the distal colon is 




and some toxic compounds containing phenolic and sulfur chemical moieties (Millet et al. 2010).   
 
SCFAs have direct and indirect influence on humans by affecting several tissue-specific 
functions, ranging from metabolism to immune regulation (Morrison and Preston 2016). For 
example, SCFAs have beneficial effects in energy homeostasis and appetite regulation (Frost et al. 
2014; Byrne et al. 2015). Upon reaching various tissues, SCFAs affect lipid and glucose 
metabolism (den Besten et al. 2013). Moreover, SCFAs have a profound effect on the host cells 
involved in inflammatory and immune pathways (Aoyama, Kotani, and Usami 2010; Vinolo et al. 
2011). The effects of SCFAs are affected by their concentration in gut, circulation, and other 
tissues where SCFAs are transported. The concentration of SCFAs in the proximal portion of the 
colon is about 70 to 140 mM, and it decreases to 20 to 70 mM in the distal colon (Wong et al. 
2006). SCFA concentrations vary depending on the type of food consumed and dietary intake, and 
can have profound effects on the microbial community (Conlon and Bird 2015). The compositional 
change in the gut microbiota can vary SCFA concentrations and this microbial change can be a 
result of differences in colonization history, physiological conditions, diet, antibiotics, stress, 
alcohol consumption, environment, and genetic factors (Zoetendal  A.D.L. Akkermans et al. 2001). 
 
1.1.2 Factors influencing gut-microbiota composition  
 
The gut-microbiota starts developing after birth in infants, with the help of maternal 
microbiota and  environmental factors (Fouhy et al. 2012). The gut microbial composition remains 
quite unstable up to 3-4 years of age, but is altered later under the influence of diet and disease 
conditions (Rodrı et al. 2015). Thus, every individual has a unique microbiome depending 




consumption of dietary fibers increases the production of SCFAs in the gut. Few stable isotope 
studies have been able to prove that the consumption of dietary fibers in the concentration of 60 
g/day generates 400-600 mmol/day SCFAs in the colon and provide approximately 10% calories 
to the body (Bergman 1990; Morrison and Preston 2016). However, the consumption of different 
types of dietary fibers (such as oligosaccharides, polysaccharides, and resistant starch) have 
significantly different effects on colonial microbiota composition, resulting in the generation of 
SCFAs in different concentrations (Edge 2016; Holscher 2017). Evidence suggests that dietary 
intake of indigestible fibers was greater than 100 g per day when humans consumed more of tubers, 
grasses and sedges. Consumption of dietary fibers is reduced to less than 15 g per day in the 
western diet (Mudgil and Barak 2013). 
 
 The chemical structure of SCFAs comprises of a carboxylic (–COOH) functional group 
imparting a mildly acidic character. The acidic property decreases the pH of the colon upon 
fermentation of microbiota and generation of SCFAs. A change in colonic pH has a direct 
correlation with the microbiota composition and these alternations consequently affect the 
concentration of SCFAs produced in gut (Morrison and Preston 2016). This indicates that along 
with the type of diet consumed by an individual, there is huge influence of colonic pH on gut 
microbiota and eventually on the concentration of SCFAs produced in colon. Studies have shown 
association of gut-dysbiosis with various metabolic and inflammatory diseases (Larsen and 
Vogensen 2010; Vrieze et al. 2010), confirming that the symbiotic relationship amongst microbial 
communities is a key factor to determine positive and negative effects of gut-microbiota and its 
metabolites on host health outcomes (Remely et al. 2014; Morrison and Preston 2016). Positive 




oxidation (Mollica et al. 2017), anti-inflammatory role in autoimmune diseases (Opazo et al. 2018) 
etc. are associated with both the type of microbiota and the concentration of SCFAs in the body. 
 
 Studies have shown that T2D patients are relatively depleted in bacterial species producing 
SCFAs (Wang et al. 2012; Article et al. 2015). A study by Kong et al. (2014) showed that 
overweight and obese subjects with healthier dietary pattern (less consumption of confectionary 
and sugary drinks, more consumption of yogurts and soups) had lower inflammatory markers and 
also highest microbial gene richness when compared to subjects which consumed higher amounts 
of confectionary and sugary diets. Interestingly, the dietary intake, insulin sensitivity and plasma 
inflammatory marker (Interleukin 6; IL6) of obese subjects consuming heathier diet were closer to 
control group of lean subjects. Turnbaugh et al. (2005) suggested that the compositional changes 
in the Bacteroidetes and Firmicutes species are associated to obesity in animals. They 
demonstrated that obese animals have reduced abundance of Bacteroidetes with a relative 
increased abundance of Firmicutes (Turnbaugh et al. 2005) These results were supported by a 
human study which showed a relationship between Firmicutes/Bacteroidetes ratio and obesity 
(Koliada et al. 2017). Vrieze et al. (2010) suggested that there is direct interaction between diet, 
type of microbiota and metabolism of obese vs. lean subjects. These alterations in microbiota 
affects the levels of gut metabolites such as SCFAs (mainly acetate, propionate and butyrate) 
which are known to modulate inflammatory and anti-inflammatory conditions (Arpaia et al. 2014), 
and also ameriolates diseases such as obesity and T2D (Lin et al. 2012; Den Besten et al. 2015; 
Ohira, Tsutsui, and Fujioka 2017). Thus, the positive health effects of SCFAs on lipid and glucose 
metabolism and immunity might be due to symbiosis between bacterial colonies which generates 




1.2 Short Chain Fatty Acids 
1.2.1 Concentration of SCFAs in gut 
 
Microbiota act on non-digestible carbohydrates to produce oligosaccharides, which are 
converted to monosaccharides by the process of fermentation in the gut under anaerobic 
conditions. These monosaccharides are then converted to phosphoenolpyruvate (PEP) (Berg, 
Tymoczko, and Stryer 2002) either via Embden-Meyerhof-Parnas pathway or the pentose 
phosphate pathway. The PEP can be used to generate organic acids and alcohols. SCFAs (viz. 
acetate, propionate and butyrate) are major end products of these bacterial pathways (den Besten 
et al. 2013). 
 
Of the three main SCFAs, acetate is found in the highest concentration because not only it 
is produced exogenously with the help of anaerobic bacteria, but also there is its endogenous 
release by the tissues and organs in the systemic circulation. With the help of bacteria, acetate is 
either produced by hydrolysis of acetyl-CoA or generated as end-product of the Wood-Ljungdahl 
pathway,  where CO2 is reduced to CO and is converted to acetyl-CoA with the help of methyl 
group and CoASH (Miller and Wolin 1996). On the other hand, propionate is formed either by the 
succinate pathway or by the acrylate pathway where lactate is reduced to propionate (Pryde et al. 
2002). Butyrate is produced by condensation of two acetyl-CoA moieties, or from the conversion 
of butyryl-CoA to butyrate via butyryl-CoA:acetate CoA transferase (Duncan, Louis, and Flint 
2004; Ragsdale and Pierce 2008).  Pyruvate used to produce acetate via Wood-Ljungdahl pathway 
can be interconverted to lactate and used to produce propionate in acrylate pathway and vice-versa. 
The production of SCFAs depends on the availability of NADH and concentration of enzymes 




etc. ( Pryde et al. 2002; den Besten et al. 2013). 
 
Although, much of the biochemistry of SCFAs conversion is known, accurate production 
rates of acetate, propionate and butyrate in humans are not yet not known. This is because of 
paucity of data from human intestinal samples and variability in microbiomes due to diet. 
However, several studies on rodent and swine models (Mcneil, Cummings, and James 1978; 
Hijova 2007) have indicated the molar ratio of acetate:propionate:butyrate in the colon is 
approximately 60:20:20; human subjects fed various types of dietary fibers have supported these 
results upon analyzing their blood and fecal samples (Cummings et al. 1987; den Besten et al. 
2013). Moreover, it has been observed that even though there is continuous variation in the 
concentrations of SCFAs throughout the body (highest concentration in colon region and least in 
systemic circulation), the ratio of acetate, propionate and butyrate remained consistent in colon 
and stool (Binder 2010; Cummings et al. 1987; Hijova 2007). In the current study, a mixture of 
acetate, propionate and butyrate in the molar ratio of 60:20:20 was administered in rats via 
intraperitoneal (I.P.) route. SCFAs once generated as metabolites of indigestible carbohydrates, 
are then transported via the portal circulation to liver and subsequently to other organs where they 
can be used as substrates or signaling molecules for lipid and glucose metabolism (Byrne et al. 
2015; Schönfeld and Wojtczak 2016).  
 
1.2.2. Transport of SCFAs  
 
SCFAs are found in highest concentration when in the lumen of the intestine. The 
concentration decreases as the microbial metabolites are transported across the epithelial cells of 




muscle, heart, kidney, adipose tissue and brain (Cummings et al. 1987; Ohira, Tsutsui, and Fujioka 
2017). The apical uptake of SCFAs across the cells can either occur in its dissociated form (SCFA-
) via active transport or in undissociated form (SCFAs) via passive diffusion (Figure 1.1).  
However, due to the acidic nature, SCFAs mainly exist in a dissociated form, which is either 
exchanged with bicarbonate anions or transported with the help of monocarboxylate transporters 
(MCT1/2). Thus, it is likely that active transport plays a major role in apical uptake of SCFA-
anions in comparison to passive diffusion, which occurs with undissociated SCFAs (Hadjiagapiou 
et al. 2000; Vidyasagar et al. 2005). 
 
SCFAs act as fuel for colonocytes; especially butyrate is used up as energy source of these 
cells. Isolated colonocytes from rats, as well as humans, showed production rate of 0.6, 0.2, 0.4 
𝜇mol/min/g cell weight of acetate, propionate and butyrate respectively (Clausen and Mortensen 
1995; Rey et al. 2010). However, the molar ratio found in circulation and fecal samples is 60:20:20 
which explains most utilization of butyrate by colon cells. Remaining SCFAs are transported 
across the basolateral membrane to the blood compartment (portal or peripheral blood) with the 












Figure 1.1 Schematics of transport of SCFAs across gut lumen. Majority of SCFAs are 
transported in dissociated form across the apical membrane of colonocytes by an HCO3- 
exchanger. Some SCFAs may be transported by passive diffusion. HCO3- - bicarbonate, SCFA- - 


























1.2.3. Role of SCFAs  
 
The liver takes up most of the acetate (about 70%) from the circulation (Bloemen et al. 
2009). The rest of the acetate is metabolized by peripheral organs, such as muscle, heart, kidney, 
and adipose tissue (Ballard 1974). In the liver, acetate provides energy to hepatocytes, and it also 
acts as a substrate for de novo synthesis of longer chain fatty acids (LCFAs) and cholesterol. 
Similar to acetate, propionate is also mostly taken up by liver from the portal circulation, and it 
can be used for hepatic gluconeogenesis (Cummings et al. 1987; Bloemen et al. 2009). Butyrate 
provides energy to colon cells and it undergoes oxidation to generate ketone bodies and CO2 (only 
if it reaches liver) (den Besten et al. 2013).  
 
All three SCFAs, when administered individually, have been suggested to have a positive 
influence on lipid and glucose parameters, mainly by inhibiting cholesterol and triacylglycerol 
(TG) synthesis, increasing lipid oxidation and insulin sensitivity (Byrne et al. 2015; LeBlanc et al. 
2017). This involves the role of G-protein coupled receptors GPCR 41 (aka free fatty acid receptor, 
FFAR 3) and GPCR 43 (aka FFAR 2) to which SCFAs bind and activate the pathways regulating 
lipid and glucose levels. A study by Kimura et al. (2013) found that mice overexpressing FFAR 2 
specifically in adipose tissue are protected from diet-induced obesity. The study concluded that 
activation of adipose-specific FFAR 2 inhibits accumulation of fat in adipose tissue while 
promoting metabolism of lipid and glucose in other tissues (Kimura et al. 2013).  
1.3. SCFAs mediated regulation of metabolic pathways 
Dietary fibers and their metabolites have gained much interest recently due to their roles in 




and Bird 2015; Ohira, Tsutsui, and Fujioka 2017) 




 Lipids can be divided into eight categories – fatty acids, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids and polyketides 
(Barber, Price, and Travers 2005). Each lipid category has its own specific classes and sub-classes. 
Fatty acids are the building blocks of lipids. Fatty acids are classified based on the carbon chain 
length, and the number and position of double bonds.  
1.3.1.1.1. Classification of fatty acids  
 
The chain length in fatty acids varies from two carbons to 30 carbons. Fatty acids with two 
to six carbons are SCFAs, those with seven to 13 carbons are medium-chain fatty acids, those with 
14 to 20 carbons are LCFAs, and those with 21 or more carbons are considered very long chain 
fatty acids (VLCFAs). On the basis of presence or absence of double bonds, fatty acids are sub-
classified into unsaturated fatty acids and saturated fatty acids (SFAs), respectively. Unsaturated 
fatty acids containing one double bond in its structure are known as mono-unsaturated fatty acids 
(MUFAs); those fatty acids with two or more double bonds are known as poly-unsaturated fatty 
acids (PUFAs). The position of double bonds in PUFAs is typically at third, sixth or ninth carbon 
atom from the terminal methyl group, and accordingly they are classified into omega-3 (n-3), 
omega-6 (n-6) and omega-9 (n-9) PUFAs, respectively (Figure 1.2). All of these fatty acids are 
present as major components of dietary fats and have distinct role in digestion, absorption and 





1.3.1.1.2. Role of fatty acids 
 
Fatty acids (FAs) are incorporated into blood lipids, storage lipids (e.g.: cholesteryl esters 
- ChE, TG), and also helps in the formation of membrane lipids (e.g.: phospholipids; PLs). The 
type of fatty acid and its quantity plays significant roles in contributing to health effects. Linoleic 
acid (18:2n-6, LA) and alpha linolenic acid (18:3n-3, ALA) are considered essential PUFAs. These 
fatty acids can only be obtained in the diet however, they can be used to synthesize longer chain 
PUFAs via the n-6 and n-3 pathways, involving elongation and desaturation (Figure 1.2). 
Arachidonic acid (20:4n-6, AA) is one of the most important fatty acid of the n-6 pathway, while 
eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA) are important 
fatty acids of the n-3 pathway. The n-6 and n-3 PUFA (AA, EPA and DHA) generate metabolically 
active biomolecules such as eicosanoids, docosanoids, and resolvins, which play important 
physiological roles in cellular functions like inflammation, platelet aggregation, and chemotaxis 
(Figure 1.3). The n-6 PUFAs are generally considered pro-inflammatory, while n-3 PUFAs are 
anti-inflammatory (Ratnayake and Galli 2009). The metabolites generated from AA as a result of 
the action of cyclooxygenase (COX) and lipoxygenase (LOX) are the 4-series lipoxins (LXs), 4-
series leukotrienes (LTs), 2-series prostaglandins (PGs), and 2-series thromboxanes (TXs), 
commonly known as eicosanoids. Those metabolites which are generated by the action of COX 
and LOX enzymes on EPA and DHA are known as resolvins and protectins. Each of these 







Figure 1.2 Schematic pathways of n-9, n-7, n-6 and n-3 fatty acid metabolism in mammals. 
Synthesis of monounsaturated fatty acid such as oleic acid (18:1n-9) occurs from acetyl Co-A 
with the help of acetyl-CoA carboxylase, fatty acid synthase, elongase and stearoyl CoA-
desaturase, via omega (n)-9 pathway. The substrates oleic acid, palmitoleic acid (16:1n-7), 
linoleic acid (18:2n-6) and a-linolenic acid (18:3n-3) are primary fatty acids which undergoes 
elongation and desaturation to synthesis longer-chain fatty acids via n-9, n-7, n-6 and n-3 
pathways respectively. 18:2n-6 and 18:3n-3 are essential fatty acids. Figure adapted from 

































































Figure 1.3 Synthesis of eicosanoids and docosanoids from AA (A), EPA and DHA (B). AA 
(20:4n-6), EPA (22:5n-3), and DHA (22:6n-3) undergoes either lipoxygenase or cyclooxygenase 
pathway to generate 2-, 3-, 4- and 5- series metabolites which have various physiological actions. 
AA – arachidonic acid, COX – cyclooxygenase, DHA – docosahexaenoic acid, EPA – 
eicosapentaenoic acid, HETE – hydroxyeicosatetraenoic acid, LOX – lipoxygenase, LTs – 
leukotrienes, LX – lipoxins, PGs – prostaglandins, TXs – thromboxanes.  
AA (20:4n-6)
LOX pathway COX pathway
4 LTs
LX (A4, B4) 
12-HETE
PGE2 TXA2 à TXB2
EPA (20:5n-3)
LOX pathway COX2 pathway COX2 pathway











Table 1.1: Physiological role of eicosanoids derived from arachidonic acid. 
 
LTs – leukotrienes, LX – lipoxins, PGs – prostaglandins, TXs – thromboxanes  
 
Table 1.2: Physiological role of eicosanoids and docosanoids derived from EPA and DHA 
 
DHA – docosahexaenoic acid, EPA – eicosapentaenoic acid, LTs – leukotrienes, LX – lipoxins, 
PGs – prostaglandins, TXs – thromboxanes.  
Type of eicosanoid Biological activity
4-series LTs Proinflammatory,
4-series LXs Chemotaxis, superoxide anion generation
12-HETE Stimulates glucose induced insulin secretion
PGE2 Proinflammatory, pro-aggregatory, immune response suppresor.
2-series TXs Potent vasoconstrictor, platelet aggregation





Resolvin E1 Potent anti-inflammatory
Protectin D Potent anti-inflammatory




1.3.1.1.3. Digestion, absorption and transport of lipids 
 
 Once dietary fat is hydrolyzed in the stomach, short- and medium-chain fatty acids are 
released into bloodstream, whereas LCFAs are emulsified and later stabilized by phospholipids in 
chylomicrons. Emulsified acylglycerols help in the secretion of bile and pancreatic juice; a sn-1/3-
specific pancreatic lipase produces 2-monoacylglycerols and free fatty acids as final products and 
also 1,2- and 2,3- diacylglycerols in small proportion as intermediary products (Mu and Porsgaard 
2005). The distribution of fatty acids at the sn-positions of TG influences their rates of hydrolysis 
and absorption (Karupaiah and Sundram 2007). The absorbed dietary lipids are utilized by either 
the monoacylglycerol pathway or the glycerol-3-phosphate (G3P) pathway for endogenous 
production of TGs (Lehner and Kuksis 1996). The monoacylglycerol pathway is the prominent 
one and occurs in smooth endoplasmic reticulum (ER) with the help of acyl-CoA synthetase, 
monoacylglycerol transacylase (MGAT) and diacylglycerol acyltransferase (DGAT). The G3P 
pathway is involved with generation of PLs along with re-synthesis of TG. However, G3P pathway 
is activated only when long-chain monoacylglycerols are present in dietary fats and occurs in 





Figure 1.4: Synthesis of triacylglycerols (TG) and phospholipids via glucose-3-phosphate 
pathway. Endogenous production of phospholipids and re-synthesis of TG occurs via G3P 
pathway. ACSL: acyl CoA synthase (ligase); AGPAT: 1-acylglycerol-3phosphoacyltransferase; 
CDP-choline: cytidine-diphosphate; CDS: cytidine-diphosphate diacylglycerol synthase, CCT: 
cytidine-triphosphate: phosphocholine cytidyltransferase; DGAT: diacylglycerol acyltransferase; 
GPAT: glycerol-3-phosphoacyltransferase; PA: phosphatidic acid; PC: phosphocholine; PE: 
phosphoethanolamine; PG: phosphoglycerol; PI: phosphoinositol; PPAP: phosphatidic acid 
phosphatase; PS: phosphoserine. Adapted from Raphael W. and Sordillo L.M., 2013, Int. J. Mol. 






















Different enzymes are involved in the transport of LCFAs, lysophosphatidylcholine (LPC) 
and cholesterol. For example, lysolecithin acyl transferase is used for esterification of LPC to PC, 
whereas for the similar process of esterification of cholesterol in intestine and plasma, acyl-CoA 
acyltransferase (ACAT) and lecithin: cholesterol acyltransferase (LCAT) are used, respectively. 
LCAT functions to transfer sn-2 positioned fatty acids (mainly PUFAs) from PC to cholesterol. 
Similar to cholesterol, PUFAs at sn-2 position in TG help in the absorption of these fatty acids as 
2-monoacylglycerols and thus, tend to retain PUFAs until subsequent processes of transport and 
biosynthesis of TG and PLs. Thus, the stereospecificity of FAs in the lipid structure is of 
significance.  
 
1.3.1.1.4. Metabolism of fatty acids 
 
The rate of fatty acid oxidation (FAO) is affected by the number of carbons and double bonds 
in the structure of the lipid molecule. For example, in case of SFAs, oxidation rates are in 
decreasing order starting laurate (C12:0) to stearate (C18:0). In general, lesser the number of 
carbon atoms, faster is the process of oxidation. Similarly, human as well as animal studies have 
reported that unsaturated fatty acids undergo faster oxidation than SFAs, indicating high chances 
of SFAs deposition in tissues than its oxidation (AASLD. 2014). Excess intake and deposition of 
SFAs in liver, adipose tissue, or in blood vessels can cause fatty liver disease and insulin resistance, 
thus increasing the risk of atherosclerosis, hyperlipidemia, T2D, obesity and few other diseases of 
metabolic syndrome (Cordain et al. 2005; Eaton 2006). However, it is not known whether SCFAs 







1.3.1.1.5. Fatty acyl composition of neutral lipids  
 
Those lipids with dominant hydrophobic groups in its structure are classified as neutral 
lipids. Cholesterol, ChE and TG are three predominant neutral lipids in mammalian cells; with 
more abundance of free cholesterol (FC) in plasma membranes, while ChE and TG are mainly 
packaged in chylomicrons and transported to various tissues. Structurally, ChE consists of one 
fatty acid esterified to its sterol skeleton, whereas TG consists of three fatty acids at the sn-1, sn-2 
and sn-3 positions of the glycerol backbone. These esterified fatty acids mainly comprise of 13-23 
carbons and 0-6 double bonds (Karupaiah and Sundram 2007). It is not known whether SCFAs 
alter the fatty acyl composition of neutral lipids and the consequences on host lipid metabolism.  
 
1.3.1.1.5.1. Effect of SCFAs on cholesterol metabolism 
 
Cholesterol is either obtained from diet or synthesized de novo mainly in the liver and 
intestine (Field, Kam, and Mathur 1990; Feingold and Grunfeld 2015). The rate limiting enzyme 
in cholesterol synthesis is 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), which converts 
3-hydroxy-3-methylglutaryl-CoA to mevalonate. An in vitro study showed that propionate lowers 
cholesterol synthesis rates due to a decrease in the activity of HMGCR in liver (Hara et al. 1999). 
These authors found that total cholesterol (TC) synthesis rates decreased when propionate was 
mixed in the administered diets. Isolated hepatocytes, when treated with propionate and butyrate 
separately, also showed that propionate inhibited fatty acid and cholesterol synthesis, whereas 
butyrate activated both pathways (Demigné et al. 1995). Fushimi et al. (2006) showed that when 
rats that were fed a diet with 1% (w/w) cholesterol, they showed a decrease in serum cholesterol 
levels upon supplementation with 0.3% (w/w) acetate. Acetate supplementation decreased the 




change in the mRNA expression of cholesterol 7α-hydroxylase (CYP7A1) (Fushimi et al. 2006). 
CYP7A1 is the rate-limiting enzyme in the pathway which involves breakdown of cholesterol to 
bile acids in liver. Plasma TC was decreased in male hamsters fed a high cholesterol diet (HCD) 
containing acetate, propionate or butyrate (Zhao et al. 2017). Although the effect of individual 
SCFAs have been studied on the regulation of cholesterol metabolism, no studies to date have 
investigated the effect of a mixture of SCFAs in a 60:20:20 molar ratio on cholesterol metabolism. 
The transport and storage of cholesterol mainly occurs in the form of ChE (Michael W King 2016), 
thus the type of fatty acid attached to cholesterol may be of prime importance in cholesterol 
metabolism (Rosqvist et al. 2017). No studies have investigated the effect of SCFAs on the fatty 
acyl composition of ChE.  
 
1.3.1.1.5.2. Effect of SCFAs on TG metabolism 
 
Dietary supplementation of SCFAs have been shown to prevent obesity induced by a high 
fat diet (HFD) (Lu et al. 2016). Obesity is a complex metabolic condition which involves elevated 
levels of glucose, TG, and high blood pressure. Individuals with obesity are at an increased risk of 
developing metabolic diseases like T2D and CVD and are clinically diagnosed for metabolic 
syndrome (Alberti, Zimmet, and Shaw 2005). Metabolic syndrome is characterized by abnormal 
fat accumulation, especially in adipose tissue and the liver. High levels of TG and fat accumulation 
in the liver and adipose tissue are considered very important biomarkers for metabolic dysfunction 
(Alberti, Zimmet, and Shaw 2005; I. Saito 2012).  
 
Fatty acids in the TG species are either obtained directly from diet or synthesized de novo 




enzymes in de novo fatty acid synthesis. In mammals, ACC has two isoforms – ACC1, which is 
involved in lipogenesis; and ACC2, which is involved in lipid oxidation. Both isoforms are highly 
expressed in liver (Barber, Price, and Travers 2005). For every odd-carbon in the newly 
synthesized fatty acids, the hydrogens are received from NADPH, whereas for every even-carbon 
in the fatty acids, the acetyl-CoA and water molecules contribute one hydrogen each, except for 
the methyl terminal position which receives all hydrogens from acetyl-CoA (Duarte et al. 2014). 
Along with de novo synthesis, the process of elongation and desaturation of lipids are also 
suggested to have implications in obesity (Wang et al. 2006). PUFAs, and its metabolites such as 
prostaglandins and eicosanoids, serve as ligands  for peroxisome proliferator-activated receptor 
(PPAR), thereby regulating oxidation and/or storage of lipids (Moon, Hammer, and Horton 2009; 
Georgiadi and Kersten 2012). Lipids involved in inflammatory pathways such as those composed 
of n-6 PUFAs and generating eicosanoids may have negative effects on steatohepatitis, while those 
undergoing desaturation to MUFAs with the help of stearoyl-CoA desaturase (SCD-1) may protect 
against fatty liver (Scorletti and Byrne 2013). Thus, the effect of SCFAs on various lipid and fatty 
acyl species is important to understand the impact on the regulation of TG metabolism.  
 
Mice fed a HFD supplemented with SCFAs showed a decrease in adipose tissue and hepatic 
PPAR𝛾 mRNA expression and activity,  preventing excess storage of lipids in adipose (Den Besten 
et al. 2015). This study concluded that SCFAs protect against obesity by switching from hepatic 
lipogenesis to fat oxidation in adipose tissue. In another study, mice fed a cholesterol-rich diet 
supplemented with acetic acid showed decreased TG levels in plasma and the mRNA expression 
of hepatic FAS (Fushimi et al. 2006). However, no studies to date have investigated the effects of 




1.3.1.1.6. Fatty acyl composition of phospholipids 
 
Lipids with a polar head group in its structure along with hydrophobic aliphatic chains are 
classified as polar lipids. PLs, sphingolipids and glycolipids are classified under polar lipids. Of 
them, PLs comprise of 60% of lipid mass content and have at least one phosphate group at sn-3 
position. Based on the head group, PLs are classified as: PC, phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidylserine (PS), and phosphatidylinositol (PI). In all 
mammalian cell types, PC is the most abundant phospholipid, followed by PE. The other PLs (PG, 
PS, PI), represent minor components in the cell which collectively account for approximately 25% 
of total PLs (Pradas et al. 2018). A colossal diversity of PLs molecular species is found in 
mammalian cells and this is due to remodeling of acyl-chain constituents by the enzymatic action 
of phospholipases and lysophospholipid acyltransferases (LPAT). These alterations in the fatty 
acid composition of PLs imparts varied function/s in the regulation of lipids, lipoprotein and 
whole-body metabolism (van der Veen et al. 2017).   
 
1.3.1.1.6.1. Functions of phospholipids  
 
 The major function of PLs is to maintain the structure and integrity of cell membranes. A recent 
study proposed that increased hepatic PC synthesis stimulates VLDL production (Martínez-Uña 
et al. 2015), resulting to increased hepatic accumulation of re-esterified TG (Van Der Veen, 
Lingrell, and Vance 2012).  Interestingly, along with the amount of hepatic PC, the fatty acyl 
composition of PC in hepatic membranes also regulates VLDL secretion. Studies have found that 
the hepatic enzyme lyso phosphatidylcholine acyltransferase 3 (LPCAT3) remodels newly 
synthesized PC in such a way that there is enrichment of AA in its sn-2 position (Hishikawa et al. 




with PLs containing PUFAs in the sn-2 position (Vásquez et al. 2014; Rosqvist et al. 2017). Thus, 
identification of the fatty acyl composition of PLs is of significance to understand the regulation 
of lipid metabolism. There are no studies to date on the effect of SCFAs on phospholipids fatty 
acyl composition. 
1.3.1.1.6.2. Sub-classification of phospholipids  
 
PC and PE are further classified to three sub-classes (phosphatidyl, plasmenyl and 
plasmanyl PLs) on the basis of ester, vinyl ether and alkyl ether linkages of the aliphatic chain on 
sn-1 position of the glycerol moiety (Horrocks and Sharma 1982). The PC and PE moieties with 
ester linkages, are known as diacylated PLs and are the predominant PLs in the cell membranes of 
most cell types, except for sarcolemma and neuronal cells, in which alkyl ether linkages 
predominate. The plasmenyl PLs are more commonly known as plasmalogens (PlsEtn/PlsCho) 
and these lipid species contain a fatty alcohol with a vinyl-ether bond at sn-1 position and are 
enriched with PUFAs at sn-2 position (Braverman and Moser 2012).  
Plasmalogens constitute about 15-20% of total PLs mass in humans. The brain has the 
highest abundance of plasmalogen species (Han., Holtzman., and Mckeel Jr., 2001) constituting 
about 90% of total PE species followed by heart and immune cells (about 50% of total PE); the 
liver has the least abundance. The lower abundance in liver relative to other tissues could be 
explained by the synthesis of plasmalogens in liver and transport to other tissues with the help of 
lipoproteins (J. E. Vance 1990). Due to varied tissue distribution, the identification of 
physiological roles of plasmalogen species have been quite challenging, as it is likely that the 
functions are specific to a particular tissue. Few of the known physiological roles of plasmalogens 




(Broniec et al. 2011). Plasmalogens also act as reservoirs for AA and DHA, and as biologically 




Lipidomics is rapidly growing analytical tool for the comprehensive identification and 
characterization of lipid constituents mediating life processes. In other words, lipidomics is a part 
of omics science that facilitates the study of lipid molecular species, also known as lipidome, in 
biological samples (plasma, blood, urine, tissue) (Han and Gross 2005). Lipidomics can be divided 
into two approaches: 1) targeted lipidomics, which focuses on the analysis of definite lipid groups 
of interest in a sample; and 2) untargeted lipidomics, which detects all possible lipid groups in a 
sample. Both of these approaches can characterize the identified molecular species in an absolute 
quantitative (expressed in molar units) or semi-quantitative manner (expressed in arbitrary units) 
(Cajka and Fiehn 2016). The targeted analyses rely on specific isolabeled internal standards that 
are added to a sample during lipid extractions, which allow for quantitative analyses. In contrast, 
untargeted lipidomics is not a quantitative approach and it can be performed with or without 
internal standards. The analyses obtained by untargeted lipidomics cannot be directly compared to 
other studies but are accurate for treatment/control comparisons. For each approach, until the mid-
2000s, there has been lack of highly sensitive analytical techniques for accurate measurement of 
lipidome (Han and Gross 2005). However, advances in mass spectrometry technologies have 
facilitated great knowledge and understanding in terms of information on elemental composition 
and molecular structure of lipid species in a biological sample (Watson and Sparkman 2007). 
Techniques using electrospray ionization mass spectrometry (ESI/MS) and Orbitrap technology 




1.3.2. SCFAs and glucose metabolism 
 
The balance between glucose intake and its utilization is of utmost importance to maintain the 
normal plasma glucose levels. Activation of FFAR 2 and 3 receptors by SCFAs increases gut 
hormones, which have a direct effect on plasma glucose levels (den Besten et al. 2013; Morrison 
and Preston 2016). SCFAs have also been shown to reduce plasma free fatty acids (FFAs) levels 
by activating FAO, inhibiting lipolysis in adipose tissue and de novo synthesis in liver (Morrison 
and Preston 2016; Ohira, Tsutsui, and Fujioka 2017). Acetate, propionate and butyrate prevented 
HFD induced obesity and insulin resistance in mice (Lin et al. 2012). Butyrate and propionate, but 
not acetate, reduced food intake by inducing gut hormones. Acetate and propionate when 
administered orally in diabetic hyperglycemic mice reduced glycaemia (Sakakibara et al. 2006). 
Moreover, propionate and butyrate generated by feeding soluble fibers in rats promoted reduction 
in body-weight by activating intestinal gluconeogenesis (De Vadder et al. 2014). Others have also 
shown that acetate, propionate and butyrate increase insulin sensitivity ( Yamashita et al. 2007; Z. 
Gao et al. 2009). However, it is yet not known if the mixture of SCFAs in a molar ratio of 60:20:20 
will improve plasma glucose and non-esterified fatty acid (NEFA) concentrations.  
1.4.  Sex-specific differences in metabolism 
 Majority of the studies conducted to date on the effects of SCFAs on glucose and lipid 
metabolism have used males. There are undisputable evidences suggesting differences in 
metabolism of males and females. It is well known that the sex-specific differences in metabolism 
are mainly due to genetic make-up and varied concentration of sex hormones like estrogens and 
androgens (Oleg Varlamov, Bethea, and Roberts 2014). Due to a difference in sex chromosomes 




glucose homeostasis in mouse model have been demonstrated between males and females (Link 
et al. 2013). Estrogens and progesterone in females, and testosterone in males, are well 
documented to regulate energy intake and energy utilization in rodents as well as humans 
(Sugiyama and Agellon 2012). Females tend to store more lipids, whereas males oxidize more of 
body fat and therefore, women have more percentage of body fat but lesser visceral white adipose 
tissue (V-WAT). Studies have shown that lesser V-WAT and higher subcutaneous WAT in body 
fat distribution is a favorable condition for homeostasis in lipid and glucose metabolism, and thus 
prevents metabolic diseases associated to abdominal obesity (Vague 1956; Snijder et al. 2005; 
Hernandez et al. 2011). FABP-2 deficient male mice are more vulnerable to develop fatty liver 
compared to female mice when fed a HFD (Sugiyama and Agellon 2012). FABP-2 deficiency 
causes an increase in fatty acids released into the portal circulation, which could lead to an overload 
of lipids in male livers, whereas the protection in female mice could be a result of compensatory 
mechanisms in female intestines.  
 
It is also known that females have a higher sensitivity towards insulin compared to males (O 
Varlamov and Bethea 2015). When male and female rats were treated with 0.1-10 nmol/L insulin, 
there was stimulation of glucose uptake in males whereas inhibition of glucose uptake was 
observed with female rats. Estrogen is known to reduce hepatic lipogenesis and increase lipolysis 
in adipocyte and thus decrease de novo synthesis. (Bryzgalova et al. 2008; D’Eon et al. 2005; H. 
Gao et al. 2006). Although men have lower body fat mass, there is a higher risk of T2D and obesity 
due to greater whole-body insulin sensitivity in women (Frias et al. 2001; Soeters et al. 2007). 
Human studies have also shown that there is more utilization of glucose in women compared to 




rats have greater resistance towards HFD and higher insulin sensitivity (Corsetti et al. 2000; 
Macotela et al. 2009; Trevaskis et al. 2008). One of the main reason for more storage as well as 
utilization of glucose and lipids in females is increased energy utilization during phases of 
menstruation and lactation.  
Another proposed mechanism for changes in lipid and glucose metabolism by SCFAs is the 
effect of gut hormones during the digestion and absorption of dietary fibers (Freeland and Wolever 
2010). When SCFAs were infused in the colon of male animals or given as dietary fibers, there 
was an increase in gut hormone concentrations in blood (Cuche, Cuber, and Malbert 2000; Zhou 
et al. 2008), suggesting a role of SCFAs and gut hormones in communication between tissues. A 
study by Freeland and Wolever (2010) showed that when female subjects were administered 
sodium acetate via intravenous and rectal routes, there was an increase in plasma Peptide YY 
(PYY) and glucagon-like peptide (GLP) levels to regulate weight management (Freeland and 
Wolever 2010). It is therefore important to understand whether SCFAs have sex-specific effects 
on the regulation of glucose and lipid metabolism.  
 
1.5 Rationale  
To date, several studies have shown beneficial effects of individual SCFAs on the 
regulation of lipid and glucose metabolism. However, the effect of SCFAs mixture (acetate, 
propionate and butyrate; 500mg/kg), in the molar ratio of 60:20:20 (produced under symbiotic 
conditions) on the regulation of lipid and glucose metabolism is not known. Moreover, the sex-
specific effects of SCFAs on the regulation of lipid and glucose metabolism are not known. In the 




of acetate, propionate and butyrate in the molar ratio of 60:20:20 for seven days. I.P. administration 
mimics the transport pathway of endogenously generated SCFAs, whereby SCFAs once produced 
in gut are transported to the liver via portal circulation. Moreover, administration by I.P. route 
eliminates the effects of SCFAs derived in gut with the help of microbiota.  
 
The animal model in the study was previously used by our collaborator, Dr. Raymond 
Thomas (Department of Environmental Science, Memorial University of Newfoundland), to 
investigate the effects of SCFAs on brain health. Dr. Thomas’s group used tissues from the current 
study to investigate the regulation of lipids and lipidomic profile of the brain. An untargeted 
lipidomics approach was used to evaluate the effects of SCFAs on plasma and hepatic lipid 
metabolism in Long-Evans rats. 
 
There are several drug therapies to prevent and/or treat metabolic diseases caused by the 
dysregulation of lipid and glucose metabolism. One of the main drawbacks of these modern 
medicines is cost, as many of these medications are not affordable by people of all socio-economic 
classes. Establishing the beneficial effects of SCFAs may suggest these as a cheaper therapeutic 
strategy for chronic diseases which require long-term treatment. To understand the role of SCFAs 
on lipid and glucose metabolism, and to investigate their sex-specific effects, the following 






1.6 Hypotheses and Objectives 
Hypothesis 1: SCFAs when given intraperitoneally in the molar ratio of 60:20:20 will decrease 
plasma and hepatic cholesterol and TG levels, and plasma glucose levels in a sex-specific manner, 
by regulating genes involved in hepatic lipogenesis.  
Objective 1a: To measure plasma and hepatic lipid levels, plasma glucose levels, and to 
investigate sex-specific effects of SCFAs on lipid and glucose metabolism; 
Objective 1b: To measure the mRNA expression of genes regulating cholesterogenesis and  
lipogenesis. 
Hypothesis 2: SCFAs, due to its role in biosynthesis of LCFAs, will alter plasma and hepatic 
lipidomic profile of various lipid classes. 

























2.1 Animals  
Long-Evans rats (12 males and 12 females; 45-50 days old) were obtained from Charles River 
Laboratories, Canada. All the animal procedures were in accordance with the Guidelines of the 
Canadian Council on Animal Care and were approved by the Animal Care Committee of Memorial 
University of Newfoundland (protocol #16-01-RT). The animals were housed in individual cages 
in a well-ventilated room and maintained under standard laboratory conditions (21℃	and 12 hours 
light/dark cycle). After one week of acclimatization, male and female rats were divided into control 
and treatment groups (n=6 in each group). Control group received 0.1 M phosphate-buffered saline 
(PBS; pH 7.4) solution at 2 mg/kg body mass, whereas treatment groups received a mixture of 
sodium acetate (Cat # S2889, Sigma-Aldrich, USA), sodium propionate (Cat # P1880, Sigma Life 
Science, USA), and sodium butyrate (Cat # B6887, Sigma-Aldrich, USA), dissolved in 0.1 M PBS 
in the molar ratio of 60:20:20, respectively. Treatment was given at a dose of 500 mg/kg body 
mass via I.P. route, each day for seven days at 7:00 AM.  Animals had free access to chow diet 
(Cat #7012; Teklad Laboratory Animal Diets, USA) and water throughout the experimental period. 
Animals were weighed each morning before administration of I.P. injection, and the amount of 
vehicle control and treatment was calculated according to the body weight. Food intake was 
measured daily after three hours of injection. 
2.2 Blood and tissue sampling  
After one week of treatment, rats were euthanized 20 mins post last injection in a non-fasted 
condition. Rats were subsequently killed by cardiac puncture under isoflurane. Blood samples 
were collected into EDTA-coated (0.1 M, 300 𝜇l) tubes and centrifuged for 10 mins at 2100 ×g 




plasma stored on ice at 4℃. Remaining plasma samples were stored at -80℃ for further analysis. 
Liver was collected, freeze-clamped and weighed immediately. Brain and abdominal fat was 
isolated, weighed, snap-frozen in liquid nitrogen. Tissues were stored at -80℃	until further 
analysis. A small portion of liver, right brain and plasma for each animal was shipped on dry ice 
to Dr. Thomas’s laboratory, Department of Environmental Sciences, Memorial University of 
Newfoundland, for lipidomics analysis by UHPLC-MS/MS. 
2.3 Lipid Extraction 
2.3.1 Folch Extraction for biochemical analysis 
 
Total lipids were extracted from liver and adipose tissue (100 mg tissue)  using 300	𝜇l of 50 
mM sodium chloride solution and 1.5 ml chloroform: methanol (2:1 v/v) mixture according to the 
Folch method (Folch, Lees, and Stanley 1957). The bottom organic layer was transferred to pre-
weighed glass vials and dried under nitrogen. Extracted lipids were re-suspended in isopropanol 
and used for biochemical analysis.  
 
2.3.2. Lipid Extractions Using Bligh-Dyer method for lipidomics 
 
Lipids for UHPLC-MS/MS analysis were extracted using a modified Bligh and Dyer method 
(Bligh, E.G. and Dyer 1959; Vidal et al. 2018). In this method, 1 ml methanol containing 0.01% 
butylated hydroxytoluene was added prior to homogenization to prevent oxidation of lipids. 
Homogenized samples were treated with 1 ml chloroform and 0.8 ml water, and centrifuged for 
10 mins at 10,000 x g. The organic layer was recovered and dried under nitrogen gas.  The extracted 





2.4. Analysis of biochemical parameters 
2.4.1 Plasma and hepatic total cholesterol  
 TC was assayed according to manufacturers’ instructions using commercially available kit 
# 234-60 (Genzyme Diagnostics, Canada). The assay uses cholesterol esterase enzyme, which 
hydrolyzes ChE to FC; the generated FC is oxidized to cholest-4-ene-3-one generating hydrogen 
peroxide (H2O2) molecule using cholesterol oxidase enzyme. The H2O2 generated during this 
reaction yields chromogen as a result of condensation reaction with 4-aminoantipyrine and p-
hydroxybenzoate. The absorbance of a generated chromogen was measured at 500 nm. All assays 
were performed in duplicates and the average absorbance values were used for calculations. The 
concentration of the samples was calculated with the help of slope obtained from the standard 
curve that was performed for each independent assay run.  
 
2.4.2 Plasma and hepatic free cholesterol and cholesteryl esters   
FC and ChE were assayed in plasma and liver samples using thin layer chromatography 
coupled to a flame ionization detector (TLC-FID) (Zhau S., 2003). A solvent system made of 
benzene:chloroform:formic acid (70:30:0.5 v/v/v) was poured into a TLC tank and allowed to 
incubate at room temperature for atleast one hour.  A standard mixture containing 1 mg/ml of 
cholesterol, TG, ChE, FFA, monoacylglycerols, and diacylglycerols was used. Before the spotting 
of standard and samples, blank scanning was performed on a rack containing ten Chromarods on 
an Iatroscan TLC-FID analyzer using a scanning speed of 4mm/sec, airflow of 2000ml/min and 
hydrogen flow of 160 ml/min.  Standard mixture (2𝜇𝑙) was applied on first rod of each rack with 
ten Chromarods followed by 2𝜇𝑙 of sample solution on the following nine rods, using a pressure 




humidity chamber containing saturated NaCl solution and was allowed to incubate for 10 mins. 
The Chromarod rack was immediately transferred to the TLC chamber developed using the solvent 
system of benzene:chloroform:formic acid (70:30:0.5 v/v/v) and incubated for 45 mins at room 
temperature.  Chromarod rack was dried for 2-3 mins at 100℃ in oven and later, scanned on an 
Iatroscan TLC-FID analyzer using same settings as described for blank scans. Analysis of peak 
areas was done using Iantroscan MK-6s along with Peak 432-64bit software.  
 
2.4.3 Plasma, hepatic and adipose tissue triacylglycerols 
 
 TG assay was performed according to manufacturers’ instructions using commercially 
available kit #236-17 (Genzyme Diagnostics, Canada). The assay uses lipase enzyme which 
hydrolyzes TG to glycerol and FFAs. The generated glycerol is further phosphorylated to glycerol-
1-phosphate with the help of ATP and enzyme glycerolkinase.  The glycerol-1-phosphate is further 
oxidized with the help of glycerol phosphate oxidase and produces H2O2, that yields a chromogen 
after coupling with 4-aminoantipyrine and p-chlorophenol. The absorbance of the chromogen was 
measured at 520 nm. All assays were performed in duplicates and the average absorbance values 
were used for calculations. The concentration of the samples was calculated with the help of slope 
obtained from the standard curve that was performed for each independent assay.  
 
2.4.4 Plasma non-esterified fatty acids 
	
NEFA was assayed according to manufacturers’ guidelines using commercially available kit 
# 278-76491 (WAKO chemicals, USA). The assay uses acyl-CoA synthetase enzyme to form thiol 




generating H2O2. The H2O2 generated during this reaction yields purple colored chromogen as a 
result of coupling with 4-aminoantipyrine and 3-methyl-N-ethyl-N-(B-hydroxyethyl)-aniline. The 
absorbance of the chromogen was measured at 550 nm. All assays were performed in duplicates 
and the average absorbance values were used for calculations. The concentration of the samples 
was calculated with the help of slope obtained from the standard curve that was performed for each 
independent assay.  
 
2.4.5. Plasma glucose 
 
Glucose was assayed according to manufacturers’ guidelines using commercially available kit 
# 10009582 (Cayman chemicals, USA). The assay uses glucose oxidase enzyme to produce delta-
gluconolactone with simultaneous production of reduced flavin adenine dinucleotide molecule and 
H2O2. The H2O2 generates pink colored chromogen as a result of condensation with 3,5-dichloro-
2-hydroxybenzenesulfonic acid and 4-aminoantipyrine. The absorbance of the chromogen was 
measured at 514 nm. All assays were performed on plasma samples (5 𝜇l) in duplicates and the 
average absorbance values were used for calculations. The concentration of the samples was 
calculated with the help of slope obtained from the standard curve that was performed for each 
independent assay.  
2.5 Gene expression analysis 
Total RNA was extracted from liver and adipose tissue samples using Trizol reagent (Cat 
#15596026; Thermo Fisher Scientific, USA). The integrity of extracted RNA was assessed using 
gel electrophoresis (1.2% agarose gel).  The concentration of extracted RNA was determined with 




contamination was removed after treatment with DNase (Cat #M610A 12358503; Promega, USA). 
Reverse transcription was performed to generate cDNA (Cat #A3500; Promega, USA), using 1𝜇g 
of RNA which was later amplified for quantitative real-time PCR (qPCR) using iQ-SYBR Green 
Supermix (Cat #170-8880; Bio-Rad Laboratories. Inc., USA). All qPCR reactions were run at a 
reaction volume of 10 𝜇l using 50ng cDNA per reaction. Samples were run using the CFX96TM 
Real-Time System, and data output was managed using the CFX ManagerTM Software Version 
3.0. Primers for lipogenic and adipogenic genes (Table 2.1) were designed using NCBI primer 
blast (www.ncbi.nlm.gov/tools/primerblast/) and obtained from IDT technologies (IA, USA). 
Relative mRNA expressions for hepatic genes were standardized to 𝛽-actin as the housekeeping 
gene, whereas glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping 
gene for adipose tissue. The ∆∆CT method (Livak and Schmittgen 2001) was used to calculate 






Table 2.1: Primers for the gene of interest and housekeeping genes 
Name of the gene Base 
pairs 









98 Forward ATT GCA CCG ACA 
AGA AAC CTG CTG 
 
Reverse TTC TCT CAC CAC 






101 Forward TGT AGA AAC 
CCGAAC CGT GG 
 
Reverse CTG GAA ACC AAA 






98 Forward GCT GCT ACA AAC 
AGG ACC AT 
 
Reverse TCC ACT GAC TCT 






89 Forward ACG CAC CTC GCT 
ATT CTC 
 
Reverse AGG CTG CTT TCA 







89 Forward TGA TAT CGA CCA 
GCT GAA CC 
 
Reverse TCA GCG GGA AGG 
ACT TTA TG 
 
112.17 NM_013124.3 
𝛽-actin (Actb) 85 Forward AGC GTG GCT ACA 
GCT TCA CC 
 
Reverse AAG TCT AGG GCA 







99 Forward TGC CAC TCA GAA 
GAC TGT GG 
Reverse TTC AGC TCT GGG 





2.6 Lipidomics Analysis 
 
HPLC grade acetic acid, formic acid, ammonium acetate, and ammonium formate were 
obtained from Sigma-Aldrich, Canada. HPLC grade acetonitrile, chloroform and methanol were 
purchased from Fisher Scientific, Canada, and deionized water was purchased from PURELAB 
Purification System (ELGA Lab-water, Canada). For internal standards, the synthetic odd chain 
PC 17:0/14:1(9Z), PE 17:0/14:1(19Z), PS 17:0/14:1(9Z) and PI 17:/14:1(9Z) were used. In order 
to verify the method, both natural as well as synthetic external standards were used. A complex 
lipid standard mixture (10𝜇l) was prepared using individual lipid classes. The standard mixture 
included lipids from natural sources as plant sulfoquinovosyl diacylglycerol (SQDG) 16:0/16:0, 
plant monogalactosyldiacylglycerol (MGDG) 16:3 (7Z,10Z,13Z)/18:3(9Z,12Z,15Z), chicken egg 
PG 18:0/20:4(5z,8z,11z,14z), porcine brain PC 18:0/20:4(5Z,8Z,11Z,14Z), porcine brain 
plasmalogen LPE P-18:0, porcine brain SM d18:1/18:0, bovine liver PI 
18:0/20:4(5Z,8Z,11Z,14Z), bovine heart dilysocardiolipin (DLCL) 18:2(9Z,12Z)/18:2(9Z,12Z), 
and bovine heart CL 18:2/18:2/18:2/18:2. Synthetic lipid standards included - PA 
18:1(9Z)/18:1(9Z), LPA 20:4(5Z,8Z,11Z,14Z), LPE 18:0, LPC 18:1(9Z), plasmalogen PC P-
18:0/20:4(5Z,8Z,11Z,14Z), plasmalogen PE P-18:0/20:4(5Z,8Z,11Z,14Z), 
monomethylphosphatidylethanolamine (MMPE) 16:0/16:0, dimethylphosphatidylethanolamine 
(DMPE) 16:0/16:0, diether PC O-18:0/O-18:0, diether DG O-20:0/O-20:0, DG 
18:0/20:4(5Z,8Z,11Z,14Z), medium chain TGs 8:0/8:0/8:0  and long chain TG 
16:0/16:0/16:0. Each lipid class was purchased from Avanti Polar Lipids (Alabaster, USA).  
 
The complex lipid standard mixture and lipids extracted from the samples (as per the method 




coupled with ultra-high performance liquid chromatography and heated electrospray ionization 
high resolution tandem mass spectrometry (UHPLC-C30RP-HESI-HR-MS/MS) using a Q-
Exactive Orbitrap mass spectrometer (Thermo Scientific, USA) (Vidal et al. 2018).  XCalibur 
software 4.0 (Thermo Scientific, USA) was used for instrument operation. Linear standard curves 
for each standard within the range of 1-10 µg/mL was used to provide quantification of the 
observed lipids. These outputs displayed excellent linear relationships between lipid concentration 
and the extracted ion chromatogram (XIC) peak areas. 
 
 The extracted lipids were analyzed using a Orbitrap mass spectrometer coupled to an 
automated Dionex Ultimate 3000 UHPLC system, controlled by Chromeleon software; the entire 
instrument was controlled by XCalibur software 4.0. Full scans of mass spectra were obtained in 
negative and/or positive modes. The parameters listed in table 2.2 were used for the Orbitrap mass 








Table 2.2: Parameters used for Orbitrap mass spectrometer 
 
Parameter 
Sheath gas 40 
Auxiliary gas 2 
Ion spray voltage 3.2 kV 
Capillary temperature 300 oC 
S-lens RF 30 V 
Mass range 200-2000 m/z 
Resolution (full scan mode) 70,000 m/z 
Resolution (top-20 data dependent MS/MS) 35,000 m/z 
Collision energy 35 (arbitrary unit) 
Injection time 35 minutes 
Isolation window 1 m/z 
Automatic gain control 1 e5 (w/ dynamic exclusion setting of 5.0s) 
Target database Q-Exactive 
Precursor tolerance 5 ppm 
Product tolerance 5ppm 
Product ion threshold 5 % 
m-score threshold 2 % 
Quan m/z tolerance ±5 ppm 
Quan RT range 1 minute 
Adduct ions for positive ion mode [M+H]+ and [M+NH4]+ 





XCalibur 4 and LipidSearch 4.1 (Mitsui Knowledge Industry, Japan) software were used 
to acquire and process all MS data. The identification and semi-quantification of all the lipid 
classes and its sub-classes, along with lipid molecular species involved with each class were 
conducted using LipidSearch software. PC, LPC, TG, ChE lipid classes were identified in positive 
ion mode ([M+H]+ and [M+NH4]+), whereas PE, LPE, PS, PI and PA classes were identified in 
negative ion mode ([M-H]-, [M+HCOO]-, [M+CH3COO]- and [M-2H]2-). Following 
identifications, the observed lipid classes and molecular species were aligned and merged using 
the alignment parameters. The alignment parameters were first optimized using lipid standards 
followed by application to untargeted lipidomic analysis. Positions of the fatty acids present in the 
molecular species found in each lipid class of the samples evaluated were identified based on the 
fragmentation patterns of the MS/MS spectra, and manually confirmed using XCalibur 4. 
2.7 Data Analysis 
Statistical analyses were performed using two-way analysis of variance (ANOVA) (treatment 
and sex as the two parameters) followed by Tukey’s post-hoc analysis using GraphPad Prism 
(Version 6.0; GraphPad Software Inc., USA). The significance level was set at P < 0.05. The 
Grubbs’ outlier test was performed for all lipidomics data using XLSTAT software. Principal 
component analysis (PCA) were used to group the lipid outputs base on similarities or differences; 
more than 60 % of variance was taken into account for each lipid class analyzed for lipidomics. 
Two-way ANOVA was used to assess the significance of the clusters or groups observed on 
selected lipid molecular species, following PCA analysis. Lipid species clustered around control 
and treatment quadrants in the PCA biplot were selected for post-hoc analysis. PCA has been 




and minimize re-projection error. However, due to assumptions made in this technique for 
linearity, larger covariance and orthogonality (Parsons, Cooper, and Albertson 2009), and also, the 
inability of PCA to detect slightest of invariance (Karamizadeh et al. 2013), few important 
components are treated as noise and removed during analysis. In the current study, analysis was 
also performed on TG lipid species not found in control and treatment quadrants of the PCA output 
as some of these species are well known for their involvement in the regulation of metabolic 
























3.1. Effects of SCFAs on the regulation of metabolic pathways 
3.1.1. Effect of SCFAs on body weight, organ weight, food intake, plasma glucose and 
NEFA concentrations 
 
Body weight and food intake of Long-Evans, for each day, over the seven days period is 
shown in Figure 3.1; while the body weight and food intake at day seven is presented in Table 3.1. 
There was no significant difference in body weight (Figure 3.1A) or food intake (Figure 3.1B) 
between control and treatment groups, for both males and females, on each day of the treatment 
including day seven (Table 3.1). However, males (both control and treatment groups) had 
significantly higher body weight (p<0.0001), as well as food intake (p<0.001), compared to female 
control and treatment groups over the seven days period and at the end of the study period (Table 
3.1). 
 
Organ (liver, abdominal fat, brain) weights of male and female rats, on day seven, are given 
in Table 3.1. There was no significant effect of treatment on liver weight of both male and females, 
compared to their respective control groups. However, males (both control and treatment groups) 
had significantly higher liver weight (p<0.0001), compared to female control and treatment groups, 
respectively. No significant difference was observed in abdominal fat in males or females, 
compared to their respective control groups; however, males treated with SCFAs had higher 
abdominal mass (p<0.01), compared to SCFAs treated females. Males treated with SCFAs showed 
significantly lower (p<0.05) levels of plasma glucose, compared to its control group; however, 
there was no effect of SCFAs on plasma glucose levels of females, compared to its control group. 
There was no effect of SCFAs treatment on NEFA levels in both males and females, compared to 





                    
 B. 
  
Figure 3.1: Effect of short chain fatty acids on A) body weight and B) food intake of animals 
from day 0 to day 7 of the study period. Data were analyzed using Dunn’s test for linear 
regression. All data are expressed as mean ± SD. P < 0.05 was considered significant (n=6). 
















































 Table 3.1: The effect of SCFAs on body weight, food intake, organ weight, plasma glucose 
and NEFA concentrations of Long Evans rats on day 7. 
 
Parameter MC MT FC FT 
(grams) 
Body weight 300.33 ± 18.79a 301.83 ± 8.57a 214 ± 7.72b 203.667 ± 5.58b 
Food intake 23.00 ± 1.75a 22.33 ± 1.87a 14.60 ± 1.07b 14.80 ± 0.88b 
Liver weight  12.588 ± 1.24a 12.723 ± 1.24a 8.494 ± 0.45b 8.975 ± 0.44b 
Abdominal fat 
weight  2.032 ± 0.56ab 2.343 ± 0.43a 1.743 ± 0.28ab 1.431 ± 0.26b 
Brain weight 1.971 ± 0.16 1.979 ± 0.19 1.859 ± 0.13 1.824 ± 0.198 
  (mmol/L)   
Plasma glucose 6.38 ± 0.78a 4.76 ± 0.68b 5.52 ± 0.33b 6.01 ± 0.82ab 
Plasma NEFA 0.73 ± 0.07 0.68 ± 0.16 0.65 ± 0.12 0.60 ± 0.09 
 
Values are expressed as mean ± SD. Data were analyzed using two-way ANOVA followed by 
Tukey’s post-hoc test. Different superscripts indicate significant differences amongst groups 
within columns. P < 0.05 was considered significant (n=6). SCFAs – short chain fatty acids, MC 
– male control, MT – male treatment, FC – female control, FT – female treatment, NEFA – non-






3.1.2. Effect of SCFAs on cholesterol metabolism 
 
TC, FC and ChE concentration in plasma and liver, are given in Figure 3.2. There was a 
significant decrease in plasma TC and FC (p<0.01 concentrations in males treated with SCFAs, 
compared to their respective controls (Figure 3.2A and B, respectively). However, SCFAs had no 
effect on plasma TC and FC concentrations in females, compared to their respective controls 
(Figure 3.2A and B, respectively). Male control and treatment groups had significantly higher 
plasma TC concentrations (p<0.0001), compared to female control and treatment groups (Figure 
3.2A). There was no effect of SCFAs on plasma ChE levels in both males and females, compared 
to their respective controls (Figure 3.2C).  
 
SCFAs significantly decreased (p<0.01) hepatic TC levels in males, compared to its control 
group; however, there was no effect of treatment in females compared to its respective control 
(Figure 3.2D). There was no effect of SCFAs treatment on hepatic FC and ChE in both males and 
females, compared to their respective controls (Figure 3.2E and F, respectively). 
 
The relative mRNA expression of genes involved in regulating cholesterol metabolism is given 
in Figure 3.3. There was no effect of SCFAs treatment on the mRNA expression of HMG-CoA 
reductase in both males and females, compared to their respective control groups (Figure 3.3A). 
Furthermore, there was no effect of SCFAs on the mRNA expression of CYP7A1; however, male 
control and treatment groups had significantly lower (p<0.01) CYP7A1 mRNA expression, 




A.                                                                   B. 
             
C.       D. 
       
       E.       F.  
             
Figure 3.2: Effects of short chain fatty acids on A) plasma TC, B) plasma FC, C) plasma ChE, 
D) hepatic TC, E) hepatic FC and F) hepatic ChE. Data were analyzed using two-way ANOVA 
followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different superscripts 
indicate significant differences amongst groups. P < 0.05 was considered significant (n=6). TC – 

























































































































Figure 3.3: Effects of short chain fatty acids on the relative mRNA expression of A) 
HMGCR and B) CYP7A1. Data were analyzed using two-way ANOVA followed by Tukey’s 
post hoc test. All data are presented relative to 𝛽-actin and expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
(n=6). HMGCR – 3-hydroxy-3-methylglutaryl-CoA reductase, CYP7A1 – cholesterol 7𝛼 
hydroxylase 
 
3.1.3. Effect of SCFAs on TG metabolism 
 
Plasma and liver TG concentrations and the relative mRNA expression of genes involved in 
regulating TG synthesis are given in Figure 3.4. There was a significant decrease in plasma and 
hepatic TG (p<0.05) concentrations in males treated with SCFAs, compared to their control group 
(Figure 3.4A and B, respectively). However, SCFAs had no effect on plasma and hepatic TG 
concentrations in females, compared to their respective control group (Figure 3.4A and B, 
respectively). SCFAs treatment significantly decreased the mRNA expression of hepatic ACC1 in 
both males and females (p<0.001), compared to their respective controls (Figure 3.4C). However, 
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Figure 3.4: Effect of short chain fatty acids on A) plasma TG, B) hepatic TG, C) the relative 
mRNA expression of ACC1 and D) FAS. Data were analyzed using two-way ANOVA followed 
by Tukey’s post hoc test. The mRNA expression data is presented as relative to 𝛽-actin. All data 
are expressed as mean ± SD. Different superscripts indicate significant difference among groups. 
P < 0.05 was considered significant (n=6). TG – triacylglycerols, ACC1 – acetyl-CoA 







































































































Adipose tissue TG concentration and the relative mRNA expression of PPAR𝛾 are given 
in Figure 3.5. There was no effect of SCFAs treatment on adipose tissue TG concentrations in both 
male or females, compared to their respective controls; however, male control group had 
significantly higher (p<0.05) TG, compared to female control group (Figure 3.5A). Furthermore, 
there was no effect of SCFAs treatment on adipose tissue mRNA expression of PPAR𝛾 in both 
males and females, compared to their respective controls (Figure 3.5B). 
 
   A.                                                                      B.  
    
 
Figure 3.5: Effect of short chain fatty acids on A) adipose tissue TG, and B) the relative 
mRNA expression of PPAR𝛾. Data were analyzed using two-way ANOVA followed by Tukey’s 
post hoc test. The mRNA expression data is presented as relative to GAPDH. All data are 
expressed as mean ± SD. Different superscripts indicate significant difference among the groups. 
P < 0.05 was considered significant (n=6). TG – triacylglycerols, PPAR𝛾 – peroxisome 






















































3.2 Effect of SCFAs on ChE, TG and phospholipids fatty acid composition 
3.2.1. Effect of SCFAs on fatty acyl composition of ChE	
	
There was no detection and/or identification of ChE species composed of SFAs (16:0 or 
18:0) either in plasma or liver samples; therefore, the effect of SCFAs is only reported for the 
relative abundance of ChE – MUFAs, n-6 PUFAs and n-3 PUFAs. 
 
3.2.1.1 Effect of SCFAs on ChE fatty acid composition in plasma 
The observation chart and biplot obtained by PCA for plasma ChE is given in the Appendix 
(Figure I A and B, respectively). PCA output for plasma ChE showed a significant effect of SCFAs 
treatment in both males and females, compared to their respective controls. Each of the four groups 
(male control – MC, male treatment –MT, female control – FC, female treatment – FT) were found 
in different quadrants (Appendix figure I A). 20:4 ChE was the only lipid species found in the 
control quadrant (MC and FC). All the other plasma ChE species (ChE - 18:1, 20:4 and 22:6) were 
clustered in the treatment quadrants (MT and FT) (Appendix figure I B).  
 
 
The effect of SCFAs on the relative abundance of plasma ChE species composed of 
MUFAs is given in Figure 3.6A. Males treated with SCFAs showed significantly higher (p<0.001) 
relative abundance of plasma 18:1 ChE, compared to its control group; however, females showed 
no effect of SCFAs on ChE 18:1, compared to its control group (Figure 3.6A). Males treated with 
SCFAs showed no effect on 20:4 ChE or 22:6 ChE in plasma, compared to their respective controls 
(Figure 3.6B and C, respectively). However, females treated with SCFAs showed significantly 
lower relative abundance of 20:4 ChE (p<0.001) (Figure 3.6B) and significantly higher abundance 




no effect of treatment or sex on 18:2 and 18:3 ChE, compared to the controls (Figure 3.6B and C, 
respectively). 
 
3.2.1.2. Effect of SCFAs on hepatic ChE fatty acid composition  
The observation chart and biplot obtained by PCA for hepatic ChE is given in the Appendix 
figure II A and B, respectively. PCA output for liver ChE showed a significant effect of SCFAs 
treatment in both males and females, compared to their respective controls. Each of the four groups 
were found in different quadrants (Appendix figure II A). Hepatic 18:1, -18:2, -18:3 and -20:5 
ChE were clustered in the control quadrants (MC and FC), while ChE species composed of other 
PUFAs (20:3, 20:4, 22:4, 22:5 and 22:6) were clustered in the treatment quadrants (MT and FT) 
(Appendix figure II B).  
 
The relative abundance of ChE species composed with 18:1, n-6 PUFAs and n-3 PUFAs 
in liver is given in Figure 3.7. There was no effect of SCFAs treatment on ChE species containing 
18:1 (Figure 3.7A), n-6 PUFAs – 18:2 and 20:4 (Figure 3.7B) and n-3 PUFAs – 18:3, 20:5, 22:5 
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Figure 3.6: Effect of short chain fatty acids on the relative abundance of plasma ChE 
composed of A) MUFAs, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed in mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
(n=6). ChE – cholesteryl esters, MUFAs – monounsaturated fatty acids, PUFAs – 
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Figure 3.7: Effect of short chain fatty acids on the relative abundance of hepatic ChE 
composed of A) MUFA, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed in mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
(n=6). ChE – cholesteryl esters, MUFAs – monounsaturated fatty acids, PUFAs – 

































































































3.2.2. Effect of SCFAs on TG fatty acid composition  
 
3.2.2.1 Effect of SCFAs on plasma TG fatty acid composition  
The observation chart and biplot obtained by PCA for plasma TG is given in the Appendix 
figure III A and B, respectively. PCA output for plasma TG showed a significant effect of SCFAs 
treatment only in females, compared to its controls. MC, MT and FT groups were found in same 
PCA quadrant and the FC group was found in another PCA quadrant (Appendix figure III A). 
Plasma TG species 18:0/16:0/16:0, 18:0/16:0/18:0 and 18:0/18:0/18:0 were clustered in the control 
quadrant (FC), and all the other TG species with MUFAs and 18:2 were clustered in the other three 
PCA quadrants (Appendix figure III B).  
 
The relative abundance of TG species composed with SFAs is given in Figure 3.8A. There was no 
effect of SCFAs treatment on plasma TG composed with SFAs and MUFAs in males, compared 
to its controls. However, SCFAs treated females showed significantly lower (p<0.0001) relative 
abundance of species composed of SFAs at all 3 sn-positions, TG - 16:0/16:0/16:0, -18:0/16:0/18:0 
and -18:0/18:0/18:0 (Figure 3.8A), and significantly higher (p<0.05) relative abundance of TG 
composed of MUFA at sn-2 position – 16:1/18:1/18:2 (Figure 3.8B), compared to its controls.  
 
Even though no TG species composed of n-6 PUFAs (such as 20:4) or n-3 PUFAs (such 
as 20:5 or 22:6) were found in either of the PCA quadrants (Appendix, Figure III B) due to 
physiological significance of these fatty acids, the effect of SCFAs is presented on the relative 
abundance of TG composed of 20:4, 20:5 and 22:6 at sn-2 or sn-3 position. There was no effect of 
SCFAs on plasma TG with PUFAs at sn-2 or sn-3 position (18:2, 20:4 and 22:6) in both males and 
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Figure 3.8: Effect of short chain fatty acids on the relative abundance of plasma TG 
composed of A) SFAs and B) MUFAs at sn-2 position. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 


























































































































3.2.2.1. Effect of SCFAs on hepatic TG fatty acid composition  
The observation chart and biplot obtained by PCA for hepatic TG is given in the Appendix 
(Figure V A and B, respectively). PCA output for hepatic TG showed a significant effect of SCFAs 
treatment in males, compared to its control group; MC and MT groups were found in different 
PCA quadrants (Appendix figure V A). However, PCA output showed no significant differences 
between female control and treatment groups as FC and FT groups were found in the same PCA 
quadrant (Appendix figure V A). Plasma TG species composed with 18:2 were clustered in the 
control quadrant, while TG species composed of SFAs and MUFAs were clustered in the treatment 
quadrant (MT) (Appendix figure V B). No species were found in the FC-FT quadrant.  
 
The relative abundance of TG species composed with SFAs and MUFAs is given in Figure 
3.9A and B, respectively. There was no effect of SCFAs treatment on plasma TG composed with 
SFAs in both males and females, compared to their respective controls (Figure 3.9A). Moreover, 
there was no effect of SCFAs on hepatic TG with MUFAs (Figure 3.9B), n-6 and n-3 PUFAs at 













             
 
Figure 3.9: Effect of short chain fatty acids on the relative abundance of hepatic TG 
composed of A) SFAs and B) MUFAs. Data were analyzed using two-way ANOVA followed 
by Tukey’s post hoc test. All data are expressed as mean ± SD. Different superscripts indicate 
significant difference amongst groups. P < 0.05 was considered significant (n=6). TG – 














































































































3.2.3. Effect of SCFAs on PC fatty acid composition  
3.2.3.1. Effect of SCFAs on plasma PC fatty acid composition 
The relative abundance of total diacylated, plasmalogen and ether-linked PC species is 
given in Figure 3.10. SCFAs treatment significantly increased (p<0.0001) relative abundance of 
PC diacylated species in both males and females, compared to their respective controls. However, 
there was no effect of SCFAs treatment on relative abundance of plasma PlsPC and PC-ether 





Figure 3.10: Effect of short chain fatty acids on relative abundance of plasma total PC 
species. Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test. All data 
are expressed as mean ± SD. Different superscripts indicate significant difference amongst 

































There were very few PlsPC (36:4p and 38:4p) and ether-linked PC (32:0e, 34:1e, 36:4e 
and 38:4e) species detected in plasma, contributing no more than 2% of total PC (Figure 3.10). 
Furthermore, there was no effect of SCFAs on plasmalogen- and ether-linked PC species (data not 
shown). PCA was carried out on plasma PC-diacylated species, which contributed ~98% of total 
PC. The observation chart and biplot obtained by PCA for plasma PC-diacylated species is given 
in Appendix (Figure VII A and B, respectively).  
 
PCA output for plasma PC showed a significant effect of SCFAs treatment on both males 
and females, compared to their respective controls. Each of the four groups (MC, MT, FC and FT) 
were found in different quadrants (Appendix figure VII A). PC species with 16:1 and 18:1 were 
clustered in the control quadrant (MC), while PC species composed of n-6 PUFAs (18:2 and 20:4) 
and n-3 PUFAs (22:5 and 22:6) were clustered in the treatment quadrants (MT and FT), 
respectively (Appendix figure VII B).  
 
The effect of SCFAs on the relative abundance of SFAs and MUFAs species in plasma PC 
is given in Figure 3.11A and B, respectively. Males treated with SCFAs showed a significant 
decrease (p<0.05) in the relative abundance of 18:0/16:0 PC (Figure 3.11A) and 18:0/18:1 PC 
(Figure 3.11B), compared to their control; however, females showed no effect of SCFAs on PC-
18:0/16:0 (Figure 16A) or 18:0/18:1 PC (Figure 3.11B), compared to their control. There was no 
effect of treatment on the relative abundance of 18:0/18:0 PC (Figure 3.11A) as well as 16:0/16:1, 






The effect of SCFAs on the relative abundance of n-6 and n-3 PUFAs species in plasma 
PC is given in Figure 3.11C and D, respectively. Males treated with SCFAs showed a significant 
increase (p<0.01) in the relative abundance of 16:0/18:2 PC but there was no effect on 16:0/20:4 
or -18:0/20:4 PC (Figure 3.11C) abundance, compared to its controls. On the other hand, SCFAs 
treated females showed no effect of SCFAs on either of the n-6 PUFA species. Moreover, males 
treated with SCFAs also showed a significant increase (p<0.01) in the relative abundance of 
16:0/22:6, 18:0/22:5 PC and 18:0/22:6 PC (Figure 3.11D), compared to its controls. However, 
females treated with SCFAs only showed a significant increase (p<0.01) in the relative abundance 
of 18:0/22:6 PC but no effect of SCFAs on 16:0/22:6 and 18:0/22:5 PC, compared to its control 
group (Figure 3.11D). Furthermore, there was significantly lower (p<0.0001) relative abundance 
of 18:0/20:4 PC in male control and treatment groups, compared to female control and treatment 
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Figure 3.11: Effect of short chain fatty acids on relative abundance of plasma PC-diacylated 
composed of A) SFAs, B) MUFAs, C) n-6 PUFAs and D) n-3 PUFAs. Data were analyzed using 
two-way ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. 
Different superscripts indicate significant difference amongst groups. P < 0.05 was considered 
significant (n=6). PC – phosphatidylcholine, SFAs – saturated fatty acids, MUFAs – 



























































3.2.3.2. Effect of SCFAs on hepatic PC fatty acid composition 
The relative abundance of total diacylated and ether-linked lipid species in hepatic PC is 
given in Figure 3.12. There was no effect of SCFAs treatment on the relative abundance of hepatic 
PC-diacylated and ether-linked lipid species, in both males and females, compared to their 
respective controls (Figure 3.12).  Unlike plasma, no PlsPC species were detected in liver samples. 
 
 
Figure 3.12: Effect of short chain fatty acids on the relative abundance of hepatic total PC 
species. Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test. All data 
are expressed as mean ± SD. Different superscripts indicate significant difference amongst 

























Very few ether-linked PC species (16:0e/16:0 and 16:0e/18:0) were detected in the liver 
samples, which contributed <0.5% of total PC abundance (Figure 3.12); there was no effect of 
SCFAs on these PC species (data not shown). Therefore; the PCA output was carried out only on 
hepatic PC-diacylated species. The observation chart and biplot obtained by PCA for hepatic PC 
is given in the Appendix figure VIIIA and B, respectively. PCA output for hepatic PC showed no 
significant effect of SCFAs treatment on males, compared to its control group; MC and MT groups 
were found in the same PCA quadrant (Appendix figure VIII A).  However, the PCA output 
revealed differences between female control and treatment groups; FC and FT were found in 
different quadrants (Appendix figure VIII A) Furthermore, PC species composed of n-6 PUFAs 
were clustered in the MC-MT quadrant, while PC species composed of n-3 PUFAs were clustered 
in the FC quadrant (Appendix figure VIII B).  
 
PC species fragmented to SFAs and MUFAs were not identified in the liver samples. The 
effect of SCFAs on the relative abundance of n-6 PUFAs and n-3 PUFAs species in hepatic PC is 
given in Figure 3.13A and B, respectively. Male control and treatment groups showed significantly 
higher (p<0.0001) relative abundance of hepatic 16:0/20:4 PC, compared to female control and 
treatment groups (Figure 3.13A). On the other hand, male control and treatment groups had lower 
(p<0.0001) abundance of 18:0/20:4 PC (Figure 3.13A), compared to female groups. There was no 
effect of treatment or sex on the relative abundance of liver 18:2/20:4 and 20:4/20:4 PC (Figure 
3.13A).  Furthermore, male groups (both control and treatment) had lower (p<0.0001) abundance 
of 18:0/22:6 PC compared to both female groups but there was no effect of SCFAs on 16:0/22:6 










Figure 3.13: Effect of short chain fatty acids on the relative abundance of hepatic PC-
diacylated composed of A) n-6 PUFAs and B) n-3 PUFAs. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
































































































3.2.3.3. Effect of SCFAs on plasma LPC fatty acid composition 
The observation chart and biplot obtained by PCA for plasma LPC species is given in the 
Appendix (Figure IX A and B, respectively). PCA output for plasma LPC showed a significant 
effect of SCFAs treatment in both males and females, compared to their respective controls. MC 
and FC groups were found in the same PCA quadrant, while MT and FT were found in two 
different PCA quadrants (Appendix, Figure IX A). All plasma LPC species were clustered in the 
treatment quadrants (MT and FT), except for 22:5 and 20:2 LPC that were clustered in the control 
quadrant (MC-FC) (Appendix, Figure IX B).  
 
The relative abundance of plasma LPC composed of ether- and plasmalogen-linked SFAs 
is given in Figure 3.14A. There was no effect of SCFAs treatment on plasma 16:0e, 18:0e or 18:0p 
LPC (Figure 3.14A) on either males or females, compared to their respective control groups. 
However, there was significantly higher (p<0.001) relative abundance of plasma 16:0e and 18:0p 
LPC in males treated with SCFAs, compared to their respective female control groups (Figure 
3.14A).  
 
The effect of SCFAs on the relative abundance of plasma LPC composed of SFAs and 
MUFAs is given in Figure 3.14B and C, respectively. SCFAs treatment had no effect on plasma 
LPC species composed with SFAs (16:0, 18:0 and 20:0 LPC) in either males or females, compared 
to their respective control groups (Figure 3.14B). However, there was significantly lower 
(p<0.0001) relative abundance of plasma 18:0 LPC, in male control and treatment groups, 
compared to female control and treatment groups (Figure 3.14B). Furthermore, there was no effect 




and females, compared to their respective controls (Figure 3.14C). However, male control and 
treatment groups showed significantly higher (p<0.0001) relative abundance of plasma 18:1 LPC, 
compared to female control and treatment groups (Figure 3.14C).  
 
The effect of SCFAs on the relative abundance of plasma LPC composed of n-6 PUFAs 
and n-3 PUFAs is given in Figure 3.14D and E, respectively. There was no effect of SCFAs 
treatment on the relative abundance of plasma LPC n-6 PUFAs (18:2, -20:3 and -20:4 LPC) or n-
3 PUFAs (22:5 and -22:6 LPC) in either males or females; compared to their respective controls 
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Figure 3.14: Effect of short chain fatty acids on the relative abundance of plasma LPC 
composed of A) plasmalogen- and ether-linked SFAs, B) SFAs without linkage, C) MUFAs, D) 
n-6 PUFAs, and E) n-3 PUFAs. Data were analyzed using two-way ANOVA followed by 
Tukey’s post hoc test. All data are expressed as mean ± SD. Different superscripts indicate 
significant difference amongst groups. P < 0.05 was considered significant (n=6). LPC – lyso 
phosphatidylcholine, SFAs – saturated fatty acids, MUFAs – monounsaturated fatty acids, 




































































































3.2.3.4. Effect of SCFAs on hepatic LPC fatty acid composition 
The observation chart and biplot obtained by PCA for hepatic LPC is given in the Appendix 
(Figure X A and B, respectively). PCA output showed a significant effect of SCFAs treatment in 
both males and females, compared to their respective control groups. Each of the four groups were 
found in different quadrants (Appendix figure X A). LPC species with SFAs (16:0, 20:0 and 22:0), 
n-6 PUFAs (18:2, 20:3 and 20:4) and n-3 PUFAs (22:5 and 22:6) were clustered in the control 
quadrants (MC and FC), while LPC species with MUFAs (18:1 and 20:1), plasmalogen- (18:0p) 
and ether-linked LPC (16:0e and 18:0e) were clustered in the treatment quadrants (MT and FT) 
(Appendix figure X B).  
 
The relative abundance of ether- and plasmalogen- linked SFAs in hepatic LPC is given in 
Figure 3.15A. Males treated with SCFAs showed significantly higher (p<0.0001) relative 
abundance of hepatic 16:0e and -18:0p LPC, compared to its respective controls (Figure 3.15A). 
However, females treated with SCFAs showed significantly higher (p<0.0001) relative abundance 
of 18:0p LPC, and there was no effect on 16:0e LPC, compared to its control (Figure 3.15A).  
 
 
The relative abundance of hepatic LPC composed with SFAs and MUFAs is given in 
Figure 3.15B and C, respectively. There was no effect of SCFAs treatment on hepatic LPC 
composed of SFAs (16:0, 18:0, 20:0 and 22:0 LPC) in males, compared to its respective control 
group (Figure 3.15B). However, there was significantly lower (p<0.05) relative abundance of 
hepatic – 16:0, in female treatment group, compared to its control group (Figure 3.15B). Moreover, 
there was significantly lower (p<0.05) relative abundance of 18:0 LPC in male control and 




with SCFAs showed significantly higher (p<0.0001) relative abundance of hepatic 18:1 LPC, 
while there was no effect on 20:1 LPC, compared to its control group. On the other hand, females 
treated with SCFAs showed no effect on 18:1 or 20:1 LPC, compared to its control (Figure 3.15C).  
 
The relative abundance of hepatic LPC composed of n-6 PUFAs and n-3 PUFAs is given 
in Figure 3.15D and E, respectively. There was no effect of SCFAs treatment on hepatic LPC with 
n-6 PUFAs (18:2, 20:3 and 20:4 LPC) in males, compared to its control. However, females treated 
with SCFAs showed significantly higher (p<0.01) abundance of 20:4 LPC, and there was no effect 
of treatment on 18:2 and 20:3 LPC, compared to its control (Figure 3.15D).  There was no effect 
of treatment on n-3 PUFAs (22:5 and 22:6 LPC) in both males and females, compared to their 
respective controls (Figure 3.15E). However, there was significantly lower (p<0.01) relative 
abundance of 22:6 LPC in male control and treatment groups, compared to female control and 
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Figure 3.15: Effect of short chain fatty acids on hepatic LPC composed of A) ether- and 
plasmalogen-linked LPC, B) SFAs, C) MUFAs, D) n-6 PUFAs and E) n-3 PUFAs. Data were 
analyzed using two-way ANOVA followed by Tukey’s post hoc test. All data are expressed as 
mean ± SD. Different superscripts indicate significant difference amongst groups. P < 0.05 was 
considered significant (n=6). LPC – lyso phosphatidylcholine, SFAs – saturated fatty acids, 







































































3.2.4. Effect of SCFAs on PE fatty acid composition 
3.2.4.1. Effect of SCFAs on plasma PE fatty acid composition 
The relative abundance of plasma total PE-diacylated, PlsPE and PE-ether species is given 
in Figure 3.16. Males and females treated with SCFAs showed significantly higher (p<0.0001) 
relative abundance of PE-diacylated species, compared to their respective controls (Figure 3.16). 
There was a significant decrease (p<0.0001) in relative abundance of total PlsPE in both males 
and females, compared to their respective control groups. However, there was no effect of SCFAs 
or sex on ether-linked PE species (Figure 3.16). 
 
 
Figure 3.16: Effect of short chain fatty acids on the relative abundance of plasma total PE 
species. Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test. All data 
are expressed as mean ± SD. Different superscripts indicate significant difference amongst 
































3.2.4.1.1. Effect of SCFAs on plasma PE-diacylated fatty acid composition 
 
The observation chart and biplot obtained by PCA for plasma PE-diacylated species is 
given in Appendix (Figure XI A and B, respectively). PCA output for plasma PE-diacylated 
showed a significant effect of SCFAs treatment in both males and females, compared to their 
respective controls. MC and FC groups were found in same PCA quadrant, while MT and FT 
groups were found in a different PCA quadrant (Appendix figure XI A). No species were clustered 
in control quadrant, while PE-diacylated species composed with PUFAs (18:2, 20:4, 22:4 and 
22:6) were clustered in the treatment quadrant (Appendix figure XI B).  
 
PE-diacylated species composed of SFAs were not detected in the plasma samples. The 
effect of SCFAs on the relative abundance of PE-diacylated species composed of MUFAs is given 
in Figure 3.17A. There was no effect of SCFAs treatment or sex on the relative abundance of 
plasma PE-diacylated species composed of MUFAs (16:0/18:1 and 18:0/18:1 PE) in both males 
and females, compared to their respective controls (Figure 3.17A). 
 
The effect of SCFAs on the relative abundance of plasma PE-diacylated n-6 PUFAs and n-
3 PUFAs is given in Figure 3.17B and C, respectively. SCFAs treatment showed a significant 
increase (p<0.01) in the relative abundance of n-6 PUFAs (18:0/18:2 and 18:0/20:4 PE), in both 
males and females; compared to their respective controls (Figure 3.17B). Males treated with 
SCFAs showed significantly higher (p<0.01) relative abundance of diacylated 16:0/22:6 PE, while 
there was no effect on 18:0/22:6 PE, compared to its control group. On the other hand, females 
treated with SCFAs showed no effect on n-3 PUFAs (16:0/22:6 or 18:0/22:6 PE), compared to 







        
C. 
          
Figure 3.17: Effect of short chain fatty acids on the relative abundance of plasma PE-
diacylated composed of A) MUFAs, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed 
using two-way ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± 
SD. Different superscripts indicate significant difference amongst groups. P < 0.05 was 
considered significant (n=6). PE – phosphatidylethanolamine, MUFAs – monounsaturated fatty 




















































































































































3.2.4.1.2. Effect of SCFAs on plasma PE-plasmalogen fatty acid composition 
 
The observation chart and biplot obtained by PCA for plasma PlsPE is given in the 
Appendix (Figure XII A and B, respectively). PCA output for plasma PlsPE showed a significant 
effect of SCFAs treatment on both males and females, compared to their respective controls. MC 
and FC groups were found in the same PCA quadrant, while MT and FT groups were found in 
different PCA quadrants (Appendix figure XII A). PlsPE species with MUFAs were clustered in 
the control quadrant, while PlsPE species composed with 22:5 were in the treatment quadrant 
(Appendix figure XII B).  
 
PlsPE with 20:4 and 22:6 were clustered in other PCA quadrants (Appendix figure XII B). 
PlsPE species with SFAs were not detected in plasma samples. The effect of SCFAs on the relative 
abundance of plasma PlsPE composed of MUFAs is given in Figure 3.18A. Males and females 
treated with SCFAs showed significantly lower (p< 0.0001) relative abundance of 18:0p/18:1 PE, 
compared to their respective controls (Figure 3.18A). However, there was no effect of SCFAs 
treatment or sex on the relative abundance of other plasma PlsPE species composed of MUFAs 
(16:0p/18:1, 18:1/p/18:1, 18:0p/20:1 and 18:1p/20:1 PE) in both males and females, compared to 
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Figure 3.18: Effect of short chain fatty acids on the relative abundance of plasma PlsPE 
species composed of A) MUFAs, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed using 
two-way ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. 
Different superscripts indicate a significant difference amongst groups. P < 0.05 was considered 
significant (n=6). PlsPE – phosphatidylethanolamine plasmalogen, PlsPE – plasmalogen PE, 
























































































































































The effect of SCFAs on the relative abundance of plasma PlsPE composed of n-6 PUFAs 
and n-3 PUFAs is given in 3.18B and C, respectively. Males and females treated with SCFAs 
showed significantly lower (p<0.05) relative abundance of 18:0p/20:4 PE, while there was no 
effect on 16:0p/20:4 and 18:1p/20:4 PE, compared to their respective controls (Figure 3.18B). 
Furthermore, males treated with SCFAs showed no effect on PlsPE n-3 PUFAs (16:0p/22:6, 
18:0p/22:5, 18:0p/22:6 and 18:1p/22:6), compared to their respective controls (Figure 3.18C). On 
the other hand, females treated with SCFAs showed significantly lower (p<0.001) relative 
abundance of 16:0p/22:6 and -18:0p/22:6 PE, while there was no effect on 18:0p/22:5 and 
18:1p/22:6, compared to its control (Figure 3.18C).  
 
3.2.4.2. Effect of SCFAs on hepatic PE fatty acid composition 
There was no detection of ether-linked PlsPE in liver samples. The relative abundance of 
total hepatic PE-diacylated and PE-plasmalogen (PlsPE) species is given in Figure 3.19. Males 
treated with SCFAs showed no effect on total PE-diacylated or PlsPE, compared to its respective 
controls. However, females treated with SCFAs showed a significantly higher (p<0.05) relative 
abundance of PE-diacylated species, and lower (p<0.05) relative abundance of PlsPE, compared 






Figure 3.19: Effect of short chain fatty acids on the relative abundance of hepatic total PE 
species. Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test. All data 
are expressed as mean ± SD. Different superscripts indicate significant difference amongst 
groups. P < 0.05 was considered significant (n=6). PE – phosphatidylethanolamine. 
 
3.2.4.2.1. Effect of SCFAs on hepatic PE-diacylated fatty acid composition 
The observation chart and biplot obtained by PCA for hepatic PE is given in the Appendix 
(Figure XIII A and B, respectively). PCA output for hepatic PE-diacylated showed no significant 
effect of SCFAs treatment on males, compared to their respective controls as MC and MT groups 
were found in the same PCA quadrant (Appendix figure XIII A). However, the PCA output 
revealed differences between female control and treatment groups as FC and FT groups were found 
in different quadrants (Appendix figure XIII A). Furthermore, hepatic PE-diacylated species with 
18:2 were clustered in MC-MT quadrant, while PE-diacylated species with other PUFAs (20:4, 
22:5 and 22:6) were clustered in other PCA quadrants (Appendix figure XIII B).  
 
 

























The PE-diacylated composed of SFAs was not detected in liver samples. The effect of 
SCFAs on the relative abundance of hepatic PE-diacylated MUFAs is given in Figure 3.20A. 
Males treated with SCFAs showed no effect of treatment on the relative abundance of PE-
diacylated MUFA; however, females treated with SCFAs showed a significant decrease in the 
relative abundance of hepatic diacylated 18:0/18:1 PE (p<0.0001), compared to its control group 
(Figure 3.20A). The effect of SCFAs on the relative abundance of n-6 PUFAs and n-3 PUFAs is 
given in Figure 3.20B and C, respectively. Males treated with SCFAs showed no effect of 
treatment on the relative abundance of PE-diacylated PUFAs (both n-6 and n-3); however, females 
treated with SCFAs showed a significant decrease in the relative abundance of hepatic diacylated 
16:0/20:4 PE (p<0.05), while there was a significant increase in the relative abundance of 
diacylated 18:0/20:4 PE (Figure 3.20B), compared to the respective control. Females treated with 
SCFAs also showed a significant (p<0.001) decrease in 18:0/22:5, and a significant increase in -
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Figure 3.20: Effect of short chain fatty acids on the relative abundance of hepatic PE-
diacylated species composed of A) MUFAs, B) PE-diacylated n-6 PUFAs and C) n-3 PUFAs. 
Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test. All data are 
expressed as mean ± SD. Different superscripts indicate significant difference amongst groups. P 
< 0.05 was considered significant (n=6). PE – phosphatidylethanolamine, MUFAs – 





















































































































































3.2.4.2.2. Effect of SCFAs on hepatic PE-plasmalogen fatty acid composition 
The observation chart and biplot obtained by PCA for hepatic PlsPE is given in the 
Appendix (Figure XIV A and B, respectively). PCA output for PlsPE showed a significant effect 
of SCFAs treatment for both males and females, compared to their respective controls. MT and 
FC groups were found in the same PCA quadrant, while MC and FT groups were found in two 
different PCA quadrants (Appendix figure XIV A). PlsPE species with MUFAs were clustered in 
the control quadrant (MC), while PlsPE species with PUFAs (20:4, 22:5 and 22:6) were clustered 
in the MT-FC quadrant (Appendix figure XIV B). No species were clustered in FT quadrant 
(Appendix figure XIV B).  
 
PlsPE species composed of SFAs were not detected in liver samples. The effect of SCFAs 
on the relative abundance of hepatic PlsPE composed of MUFAs is given in Figure 3.21A. Males 
treated with SCFAs showed no effect on PlsPE MUFAs; however, females treated with SCFAs 
showed a significant decrease (p<0.0001) in the relative abundance of 16:0p/18:1 and 18:0p/18:1 
PE, compared to its respective control (Figure 3.21A).  
 
The effect of SCFAs on the relative abundance of hepatic PlsPE composed of n-6 PUFAs 
and n-3 PUFAs is given in Figure 3.21B and C, respectively. Males treated with SCFAs showed 
no effect on PlsPE composed of n-6 and n-3 PUFAs, compared to their respective controls (Figure 
3.21B and C, respectively). Females treated with SCFAs showed significantly lower (p<0.0001) 
relative abundance of n-6 PUFAs, such as 18:0p/20:4 and 18:0p/22:4 PE (Figure 3.21B), and n-3 
PUFAs, such as 16:0p/22:6, 18:0p/22:5 and 18:0p/22:6 PE (p<0.0001) (Figure 3.21C), compared 
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Figure 3.21: Effect of short chain fatty acids on the relative abundance of hepatic PlsPE 
composed of A) MUFAs, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
(n=6). PE – phosphatidylethanolamine, PlsPE – phosphatidylethanolamine plasmalogen, MUFAs 




















































































































































3.2.4.3. Effect of SCFAs on plasma and hepatic LPE fatty composition 
The effect of SCFAs on the relative abundance of plasma and hepatic LPE is given in 
Figure 3.22A and B, respectively. LPE species composed of MUFAs, n-6 PUFAs and n-3 PUFAs 
were not detected in the plasma and liver samples. As very few LPE species were identified, there 
was no need of PCA output for either plasma or hepatic LPE. 
 
Males treated with SCFAs showed significantly higher (p<0.01) relative abundance of 18:0 
LPE; compared to its control group; however, females treated with SCFAs showed no effect on 
the relative abundance of plasma LPE (Figure 3.22A), compared to control. Males showed no 
effect of SCFAs treatment on the relative abundance of hepatic LPE (16:0 and 18:0), compared to 
their control; whereas, females treated with SCFAs showed a significantly lower (p<0.001) relative 
abundance of hepatic 16:0 and -18:0 LPE; compared to their respective controls (Figure 3.22B). 
A.                                                                       B. 
 
Figure 3.22: Effect of short chain fatty acids on the relative abundance of A) plasma LPE 
and B) liver LPE. Data were analyzed using two-way ANOVA followed by Tukey’s post hoc 
test. All data are expressed as mean ± SD. Different superscripts indicate significant difference 
amongst groups. P < 0.05 was considered significant (n=6). LPE – lyso 































































3.2.5. Effect of SCFAs on PI fatty acid composition 
 
There was no detection and/or identification of PI species linked with plasmalogen or ether 
moieties in either plasma or liver; therefore, the effect of SCFAs was only observed on the relative 
abundance of PI-diacylated species. Furthermore, lyso species were also not detected for plasma 
or hepatic PI. Moreover, PI species composed of SFAs and MUFAs were not detected in either 
plasma or liver samples; therefore, the effect of SCFAs was only observed on the relative 
abundance of PI species composed of n-6 and n-3 PUFAs. 
 
3.2.5.1. The effect of SCFAs on plasma PI fatty acid composition 
The observation chart and biplot obtained by PCA for plasma PI is given in the Appendix 
(Figure XV A and B, respectively). PCA output for plasma PI showed a significant effect of SCFAs 
treatment on males, compared to their controls; MC and MT groups were found in different PCA 
quadrants (Appendix figure XV A). However, the PCA output showed no differences between 
female control and treatment groups as FC and FT groups were found in the same PCA quadrant 
(Appendix figure XV A). PI species composed with PUFAs such as 18:2, 20:4, and 22:6 were 
clustered in the control quadrant (MC) (Appendix figure XV B); however, no species were 
clustered in the FC-FT quadrant (Appendix figure XV B).  
 
 The effect of SCFAs on the relative abundance of plasma PI species composed with n-6 
PUFAs and n-3 PUFAs is given in Figure 3.23A and B, respectively. Males treated with SCFAs 
showed significantly lower relative abundance of plasma 18:0/20:4 PI (Figure 3.23A), and higher 
relative abundance of plasma 18:0/22:6 PI (p<0.0001) (Figure 3.23B), compared to their respective 




compared to their respective controls (Figure 3.23A and B, respectively). Furthermore, male 
control and treatment groups had significantly higher (p<0.01) relative abundance of 16:0/20:4 PI, 




      
 
Figure 3.23: Effect of short chain fatty acids on the relative abundance of plasma PI fatty 
acid composed of A) n-6 PUFAs and B) n-3 PUFAs. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 








































































































3.2.5.2. The effect of SCFAs on hepatic PI fatty acid composition 
The observation chart and biplot obtained by PCA for hepatic PI is given in the Appendix 
(Figure XVI A and B, respectively). PCA output for hepatic PI showed no significant effect of 
SCFAs treatment on males, compared to its control group; MC and MT groups were found in the 
same PCA quadrant (Appendix figure XVI A). However, the PCA output revealed differences 
between female control and treatment groups as FC and FT were found in different quadrants 
(Appendix figure XVI A). There was no specific clustering of PI species found in either of the 
PCA quadrants (MC-MT, FC or FT) (Appendix figure XVI B). 
 
The relative abundance of hepatic PI species composed with n-6 PUFAs and n-3 PUFAs 
is given in Figure 3.24A and B, respectively. Males treated with SCFAs showed no significant 
effect on the relative abundance of PI containing n-6 PUFAs and n-3 PUFAs, compared to its 
respective controls (Figure 3.24A and B, respectively). However, females treated with SCFAs 
showed significantly lower (p<0.01) relative abundance of hepatic 16:0/20:4 PI (Figure 3.24A), 
while there was a higher relative abundance of 18:0/20:4 PI (p<0.05) (Figure 3.24A), compared to 
their respective controls. The SCFAs in females revealed a significant decrease in hepatic 



















   
 
Figure 3.24: Effect of short chain fatty acids on the relative abundance of hepatic PI 
composed of A) n-6 PUFAs and B) n-3 PUFAs. Data were analyzed using two-way ANOVA 
followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different superscripts 
indicate significant difference amongst groups. P < 0.05 was considered significant (n=6). PI – 








































































































3.2.6 Effect of SCFAs on PS fatty acid composition 
 
There was no detection and/or identification of PS species linked with plasmalogen or ether 
moieties, in either plasma or liver samples; therefore, the effect of SCFAs was only observed on 
the relative abundance of PS-diacylated species. Moreover, no lyso species were detected for either 
plasma or hepatic PS lipid class. 
  
3.2.6.1. Effect of SCFAs on plasma PS fatty acid composition 
The observation chart and biplot obtained by PCA for plasma PS is given in the Appendix 
(Figure XVII A and B, respectively). PCA output for plasma PS showed a significant effect of 
SCFAs treatment in both males and females, compared to their respective controls. Each of the 
four groups were found in different quadrants (Appendix figure XVII A). Plasma PS species 
composed of MUFAs (18:1 and 20:1) were clustered in the control quadrants (MC and FC), while 
plasma PS species composed of PUFAs (20:4 and 22:6) were clustered in the treatment quadrants 
(MT and FT) (Appendix figure XVII B).  
 
There was no identification of PS species composed of SFAs in plasma samples. The effect 
of SCFAs on the relative abundance of plasma PS species composed with MUFAs is given in 
Figure 3.25A. Males and females treated with SCFAs showed significantly lower (p<0.0001) 
relative abundance of plasma 18:0/18:1 PS (Figure 3.25A), compared to their respective controls.  
 
The effect of SCFAs on the relative abundance of plasma PS species composed with n-6 
PUFAs and n-3 PUFAs is given in Figure 3.25B and C, respectively. There was significantly 




PS (p<0.0001) in both males and females, compared to their respective controls (Figure 3.25B). 
Furthermore, both males and females showed significantly lower (p<0.05), relative abundance of 
22:4/22:6 PS compared to their respective controls (Figure 3.25C). Moreover, females treated with 
SCFAs also showed a significant decrease in the relative abundance of 18:0/22:6 PS (p<0.01), 
compared to its control group (Figure 3.25C). However, there was no effect of SCFAs treatment 
on plasma 18:1/22:6 PS in both males and females, compared to their respective controls (Figure 
3.25C). 
 
3.2.6.2. Effect of SCFAs on hepatic PS fatty acid composition 
The observation chart and biplot obtained by PCA for hepatic PS is given in the Appendix 
(Figure XVIII A and B, respectively). PCA output for hepatic PS showed no significant effect of 
SCFAs treatment on males, compared to their controls; MC and MT groups were found in the 
same PCA quadrant (Appendix figure XVIII A). However, the PCA output revealed differences 
between female control and treatment groups as FC and FT were found in different quadrants. PS 
species composed with n-6 PUFAs (18:2 and 20:4) were clustered in the MC-MT quadrant, while 
PS species composed with MUFAs (18:1) and n-3 PUFAs (22:6) were clustered in the FC quadrant 
(Appendix figure XVIII B).  
 
The effect of SCFAs on the relative abundance of PS species composed with MUFAs is 
given in Figure 3.26A. Males and females treated with SCFAs showed no significant effect on the 
relative abundance of plasma 18:0/18:1 PS, compared to their controls (Figure 3.26A). The effect 
of SCFAs on the relative abundance of PS species composed with n-6 PUFAs and n-3 PUFAs is 




treatment on hepatic n-6 PUFAs (Figure 3.26B) and n-3 PUFAs (Figure 3.26C), compared to its 
control group. However, females treated with SCFAs showed significantly higher (p<0.0001) 
relative abundance of hepatic 18:0/20:4 PS, compared to its control group (Figure 3.26B). 
Moreover, SCFAs treated females showed significantly lower (p<0.0001) relative abundance of 








                                  
C.   
                                   
Figure 3.25: Effect of short chain fatty acids on the relative abundance of plasma PS 
composed of A) MUFAs, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
(n=6). PS – phosphatidylserine, MUFAs – monounsaturated fatty acids, PUFAs – 




































































































































   
B. 
                    
C. 
                      
Figure 3.26: Effect of short chain fatty acids on the relative abundance of hepatic PS 
composed of: A) MUFAs, B) n-6 PUFAs and C) n-3 PUFAs. Data were analyzed using two-
way ANOVA followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different 
superscripts indicate significant difference amongst groups. P < 0.05 was considered significant 
(n=6). PS – phosphatidylserine, MUFAs – monounsaturated fatty acids, PUFAs – 


































































































































3.2.7. Effect of SCFAs on PA fatty acid composition  
 
3.2.7.1. Effect of SCFAs on plasma PA fatty acid composition 
The observation chart and biplot obtained by PCA for plasma PA is given in the Appendix 
(Figure XIX A and B respectively). PCA output for plasma PA showed a significant effect of 
SCFAs treatment in both males and females, compared to their controls. MC and FC groups were 
found in different quadrants while MT and FT were found in the same PCA quadrant (Appendix 
figure XIX A). PA species composed with MUFAs were clustered in the control quadrants (MC 
and FC), while PA species with PUFAs (18:2 and 20:4) were clustered in treatment quadrant (MT-
FT) (Appendix figure XIX B).  
 
PA species composed of SFAs and n-3 PUFAs were not identified in plasma samples. The 
effect of SCFAs on the relative abundance of PA species composed with MUFAs and n-6 PUFAs 
is given in Figure 3.27A and B, respectively. Males treated with SCFAs showed significantly lower 
(p<0.05) relative abundance of plasma 18:0/18:1 PA; while females treated with SCFAs showed 
lower relative abundance of plasma 16:0/18:1 PA; compared to their respective controls (Figure 
3.27A).  
 
Furthermore, there was significantly higher (p<0.01) relative abundance of plasma PA 
composed of n-6 PUFAs such as 16:0/18:2, 18:2/18:2 and 18:2/20:4 PA (Figure 3.27B) in males 
treated with SCFAs, compared to its controls. However, there was no effect of SCFAs on PA 










Figure 3.27: Effect of short chain fatty acids on the relative abundance of PA composed of 
A) MUFAs and B) n-6 PUFAs. Data were analyzed using two-way ANOVA followed by 
Tukey’s post hoc test. All data are expressed in mean ± SD. Different superscripts indicate 
significant difference amongst groups. P < 0.05 was considered significant (n=6). PA – 













































































































4.1. Effect of SCFAs on the regulation of lipid metabolic pathways 
 
4.1.1. Effect of SCFAs on body weight, organ weight, food intake, plasma glucose and 
NEFA concentrations. 
 
SCFAs have been shown to prevent weight gain, regulate appetite (Byrne et al. 2015) and 
improve glucose levels in rodents and in humans (den Besten et al. 2013; Chambers et al. 2015) . 
These beneficial effects of SCFAs are observed either indirectly (enteral route) or directly 
(parenteral route). In the current study, SCFAs mixture in 60:20:20 molar ratio showed no 
significant effect on body weight or food intake, in either males or females. Consistent with 
observations in this study, it was previously shown in male C57BL/6 mice that sodium butyrate 
when mixed in HFD at 5% w/w concentration, had no significant effect on body weight, food 
intake and fat content (Z. Gao et al. 2009). A recent study investigated the effect of acetate, 
propionate and butyrate individually, using C57BL/6 mice (sex not mentioned) fed a HFD, and 
reported no effect of treatment on body weight and food intake, compared to mice fed only HFD 
(Den Besten et al. 2015). However, in the latter study, a decrease in adipose tissue PPAR𝛾 mRNA 
expression and activity was reported, which stimulated fat oxidation in liver and adipose tissue, 
suggesting a role of SCFAs in fatty acid oxidation and energy expenditure (Den Besten et al. 2015; 
Z. Gao et al. 2009). In the current study, I did not observe any change in adipose tissue PPAR𝛾 
mRNA expression. This discrepancy may be because in the above-mentioned study, mice were 
fed a HFD and then supplemented with SCFAs.  
  
Mice on a HFD, supplemented with fermentable carbohydrates (inulin) gained less weight, 




the same study, when acetate alone was administered I.P. in the dose of 500 mg/kg body weight 
instead of supplementation of dietary fibers, there was an increase in plasma acetate levels, with a 
significant reduction in acute food intake at one and two hours post injection. On the contrary, I 
found that when a mixture of SCFAs was administered by I.P. injection at the same dosage used 
by Frost et al. (500mg/kg); there was no change in the plasma SCFAs levels (data not shown) or 
food intake of either males or females. In the study by Frost et al, the decrease in food intake was 
suggested to be due to the action of increased plasma acetate levels, where acetate acted as an 
anorexic signal in gut-brain axis (Frost et al. 2014). However, I did not find an increase in plasma 
acetate levels (data not shown), which may explain no change in food intake or body weight in my 
study.  
 
Males (control and treatment groups) had significantly higher body weight, liver weight 
and food intake, compared to female control and treatment groups, which was expected. SCFAs 
showed no effect on abdominal fat in both male and female groups; however, males treated with 
SCFAs had higher abdominal fat, compared to SCFAs treated females, indicating sex-specific 
effects. The sex-specific differences in body weight, food intake and liver weight was expected to 
be higher in males compared to females, due to differences in energy expenditure in both the sexes 
(Sugiyama and Agellon 2012). 
 
Increased plasma glucose levels, along with increased plasma and hepatic lipid levels are 
associated with a higher risk of metabolic disorders like CVD, T2D and obesity (Erion, Park, and 
Lee 2016). In the current study, males treated with SCFAs showed a significant decrease in glucose 




respective controls. It has been suggested that the effects of SCFAs on glucose metabolism depend 
on the ratio of propionate: butyrate, and not propionate or butyrate alone. Intraperitoneally 
administered acetate had no effect on blood glucose concentrations of male C57BL/6 mice (Frost 
et al. 2014), emphasizing that a combination of SCFAs, and not acetate alone, is required to 
influence blood glucose concentrations as observed in the current study.  The decrease in plasma 
glucose levels by SCFAs has been shown to be due to activation of a SCFA receptor, known as 
FFAR 2 (den Besten et al. 2013), which should be investigated in the future.  The effects of SCFAs 
on glucose concentrations were found to be sex-specific. The sex-specific differences in plasma 
glucose levels could be due to the role of estrogen in maintaining glucose homeostasis in females 
(Sugiyama and Agellon 2012). 
 
4.1.2. Effect of SCFAs on cholesterol metabolism 
4.1.2.1. Effect of SCFAs on plasma and hepatic cholesterol levels 
 In the current study, SCFA treatment caused a significant decrease in plasma TC and FC 
concentrations in males, compared to their respective controls. However, no significant differences 
were observed in plasma ChE levels in males treated with SCFAs, suggesting that the decrease in 
plasma TC levels is due to a decrease in FC levels. On the other hand, females showed no effect 
of SCFAs treatment on plasma TC, FC and ChE levels. Furthermore, males treated with SCFAs 
also revealed a decrease in hepatic TC, compared to its control group. However, SCFAs showed 
no significant differences in hepatic FC and ChE levels in both males and females, compared to 
their respective controls. Previous studies have shown that dietary fibers and its metabolites, 




SCFA-fed rats had lower plasma cholesterol levels, compared to rats fed fiber free diet (Hara et 
al. 1998). These authors found that the decrease in cholesterol levels by SCFA is not due to a 
decrease in cholesterol synthesis (Hara et al. 1999), which is similar to my findings where I did 
not find a significant effect of SCFAs on the mRNA expression of HMGCR. However, another 
group have shown that dietary acetate reduced serum cholesterol levels, which was due to a 
decrease in HMG-CoA enzyme concentration (Fushimi et al. 2006). These authors found that 
acetic acid treatment also increased fecal bile content; however, there was no change in CYP7A1 
activity or mRNA levels. Another similar study conducted on male hamsters showed that feeding 
HCD containing acetate, propionate or butyrate, decreased plasma TC, with a concomitant increase 
in fecal bile acids (Zhao et al. 2017). This group suggested that the decrease in plasma TC levels 
was due to upregulation of genes such as SREBP2, LDLR and CYP7A1, and concluded that 
SCFAs with 2-4 carbons (acetate, propionate and butyrate) are hypocholesterolemic. I did not 
measure fecal bile acids; however, the mRNA expression of CYP7A1 remained unchanged in my 
study.  
 
Dietary propionate has been shown to decrease the TC synthesis rate by reduction in the 
enzyme activity of HMGCR and HMGCS (den Besten et al. 2013). However, I did not find an 
effect of SCFAs on HMGCR mRNA expression. HMGCR is regulated at the transcriptional and 
posttranscriptional levels (Feingold and Grunfeld 2015; Michael W King 2016), and SCFAs may 
impact HMGCR enzyme activity. It is also possible that the decrease in plasma FC levels is due 
to an increase in LCAT activity. LCAT is involved in the hydrolysis of FA at sn-2 position of 
phospholipids, which then transfers the hydrolyzed FA to cholesterol to yield ChE (Sorci-Thomas, 




cholesterol is associated with a higher risk of heart diseases (Viollet et al. 2009). I did not find any 
change in plasma and hepatic levels of ChE, suggesting that the decrease in FC might be 
responsible for an overall decrease in TC levels in males treated with SCFAs. 
 
I observed sex-specific effects on the regulation of cholesterol metabolism; however, no 
studies to date have investigated the sex-specific effects of SCFAs on cholesterol metabolism. My 
findings revealed that males treated with SCFAs had lower plasma and hepatic TC levels, while 
SCFAs-treated females had no effect of treatment. In females, higher levels of estrogen are 
responsible for the reduced hepatic lipogenesis and increased lipolysis in adipocytes which leads 
to decreased de-novo synthesis of lipids (D’Eon et al. 2005; H. Gao et al. 2006; Bryzgalova et al. 
2008). However, Suligyan and Agellon (2012) suggested that the differences in sex-specific lipid 
metabolism is not solely dependent on estrogens and androgens, but other important components 
like metabolic fate of nutrient intake also contributes to this synergy. 
 
4.1.2.2. Effect of SCFAs on plasma and hepatic ChE fatty acid composition 
The fatty acid composition of plasma and hepatic ChE are associated with insulin resistance 
and blood glucose levels (Lewis-Barned et al. 2000; Rosqvist et al. 2017). For example, a clinical 
trial carried out on Finnish population found that diabetic subjects had higher levels of serum ChE 
– 18:3 (ALA), 20:3 (ETA) and 20:4 (AA), compared to non-diabetic subjects (Salomaa et al. 
1990). This clinical trial also showed differences in plasma and hepatic ChE composition. In the 
current study, I found that males had no effect of SCFAs on the plasma or hepatic ChE fatty acid 
composition. However, females treated with SCFAs showed a significant decrease in the relative 




to its control group. It is known that 20:4 ChE acts as a substrate for oxidizing agents, such as 12 
or 15-lipoxygenase; thus, the metabolites generated by 20:4 ChE are associated with 
atherosclerosis (Harkewicz et al. 2008). On the other hand, n-3 PUFAs such as 20:5 (EPA) and 
22:6 (DHA), lowers the propensity for AA metabolites (Lands 2015) that are inflammatory. My 
findings support that SCFAs reduce the incorporation of inflammatory 20:4 ChE, while increasing 
the incorporation of 22:6 that is anti-inflammatory. Others have shown that butyrate (1g/kg), when 
administered in db/db mice via I.P. route, reduced the mRNA expression of inflammatory 
cytokines (IL-1, IL-6 and TNF-𝛼) in adipose tissue (Wang X., He G., Peng Y., Zhong W., 2015). 
In the current study, SCFAs caused a higher abundance of 22:6 ChE in females, which may be 
associated with a reduction in inflammatory cytokines.   
 
The cholesterol esterification reaction is catalyzed via LCAT and ACAT2 enzymes in 
plasma and liver, respectively (Michael W King 2016). The increase in LCAT activity might be 
responsible for the decrease in plasma 20:4 ChE abundance relative to ChE 22:6, which was 
increased. I propose a pathway (Figure 4.1) for the sex-specific effects of SCFAs on cholesterol 
metabolism, where LCAT may decrease plasma TC and FC levels in males, and 20:4 ChE 
abundance in females. 
 
It was interesting to note in this study that the fatty acids identified with ChE were of n-6 
and n-3 PUFA classes. Studies have shown that the serum ChE fatty acid composition is different 
in rats and other species (Law, Field, and George 1980). Rat plasma ChE is comprised of ~50% 
AA, while rabbits have a very low ChE - AA content. On the other hand, humans tend to have 




study, the relative abundance of ChE 20:4 was ~80%; which is higher than 20:4 ChE content 
suggested for rat plasma in the literature. It is possible that the property of unsaturated ChE to 
exhibit dipole moment in ESI, might make them look artificially higher in abundance compared to 
equimolar amount of saturated ChE (16:0 and 18:0), which were not identified in this study 
(Bowden et al. 2011).  
 
 
Figure 4.1 - Proposed pathway on the sex-specific effects of SCFAs on cholesterol 
metabolism. An increase in LCAT activity may be involved in decreasing plasma and hepatic 
cholesterol levels in males, while in females, it  may decrease the abundance of ChE 20:4 and 
increase the abundance of  ChE 22:6 via independent pathways regulated via sex-hormones. .  
SCFAs – short chain fatty acids, TC – total cholesterol, FC – free cholesterol, ChE – cholesteryl 
esters, LCAT – lecithin-cholesterol acyltransferase (*indicates experiment not performed in this 
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4.1.3. Effect of SCFAs on TG metabolism 
Mammals obtain their energy in the form of fats either from dietary TG or de-novo 
synthesized TG. In the current study, all animals were fed a standard chow diet, thus, the fatty acid 
composition of dietary TG of control and treatment groups was similar, suggesting that the effects 
of SCFAs on TG metabolism are likely due to changes in de-novo synthesis.  
 
4.1.3.1. Effect of SCFAs on plasma and hepatic TG levels 
An increase in TG levels is associated with hyperlipidemia, insulin resistance, obesity, 
vascular diseases, non-alcoholic fatty liver disease and other metabolic diseases (Mu and 
Porsgaard 2005). In the current study, the SCFA mixture reduced plasma and hepatic TG levels in 
males, compared to its controls; while SCFA treated females showed no effect on TG levels in 
either plasma or liver. Studies have shown that mice and rats fed a HFD supplemented with 
propionate and butyrate, are protected against development of obesity and insulin resistance 
(Canfora, Jocken, and Blaak 2015; Lin et al. 2012). The effect of SCFAs on TG metabolism has 
been suggested to be due to an increase in FAO in multiple tissues (den Besten et al. 2013), and a 
decrease in fat storage in adipose tissue (Den Besten et al. 2015). In the current study, I found that 
SCFAs reduced the mRNA expression of hepatic ACC1 in both males and females, compared to 
their respective controls. Thus, the decrease in plasma and hepatic TG levels in males is likely due 
to inhibition of ACC1, the rate limiting enzyme in fatty acid synthesis (Mao J. et al. 2008). 
 
Previous studies have shown that SCFAs inhibit storage of fat in adipose tissue in mice fed 
a HFD (Kimura et al. 2013). Moreover, SCFAs reduced lipolysis in adipose tissue (Den Besten et 




there was no effect of SCFAs on the mRNA expression of PPAR𝛾, which was consistent with no 
change in plasma NEFA levels. This discrepancy may be because the majority of the studies on 
SCFAs treatment used animal models that were fed a HFD, while animals in the current study 
were fed a standard laboratory chow diet.  
 
Acetate gets incorporated into LCFAs in the liver, and is then utilized for the formation of 
complex lipids during the process of de-novo lipogenesis and cholesterol synthesis (den Besten et 
al. 2013). On the other hand, propionate and butyrate, have been shown to inhibit these processes. 
It has been suggested that a combination of SCFAs may negate the effects of individual SCFA on 
lipid metabolism (Morrison and Preston 2016). As in the current study, a combination of acetate, 
propionate and butyrate was used, this may also explain the differences in the effects observed on 
TG metabolism in liver and adipose tissue, compared to previously published studies that studied 
the effects of individual SCFAs on TG metabolism (Lin et al. 2012, Kimura et al. 2013, Den Besten 
et al. 2015).  
 
4.1.3.2. Effect of SCFAs on plasma and hepatic TG fatty acid composition  
The alternation in the positional distribution of fatty acids in TG species can occur either 
via switching of positions within the TG molecule or between two different TG molecules 
(Karupaiah and Sundram 2007). Due to the tendency of TG molecules to retain the fatty acid at 
sn-2 position, plasma and hepatic TG species with SFAs (16:0 and 18:0), MUFAs (16:1), n-6 
PUFAs (20:4) and n-3 PUFAs (22:6) at sn-2 position were analyzed and compared. I found that 




species, compared to its control group. However, SCFAs treated females showed decreased 
relative abundance of TG species composed of SFAs (16:0 and 18:0) at all three sn- positions.  
 
            There was no effect of SCFAs on TG species composed of MUFAs, n-6 or n-3 PUFAs, in 
either males or females, compared to their respective controls. A study conducted on hamsters 
concluded that diets rich in C18:0 and devoid of cholesterol, had lowest fat digestibility and 
greatest steroid excretion (Imaizumi K., Kuroiwa, Sugano M., 1993). TG composed of C16:0 at 
sn-2 position in palm oil showed higher levels of plasma TG in newborn piglets, compared to that 
composed of sn-2 C18:1 (Innis SM, Quinlan P., 1993). Similarly, TG composed of C16:0 at sn-2 
position in lard resulted in higher TG levels in rat plasma (Lopez-lopoz A. et al, Early Human Dev, 
2001). Positional differences in the SFAs have also been hypothesized to modulate the transport 
of n-6 and n-3 PUFAs (Innis SM and Dyer R, J nutr 1997). Thus, SCFA mediated changes in the 
fatty acid composition of TG may impact the fatty acid composition of other lipids in circulation.  
It is well known that SFAs are associated with CVD (Mensink R., 2016). I found that SCFAs-
treated males showed decreased plasma and hepatic TG levels. Even though SCFAs treated 
females showed no change in total TG levels, the relative abundance of TG species composed of 
16:0 and 18:0 was significantly decreased, compared to its control group. Thus, SCFA mediated 
alterations in TG fatty acyl species may be of importance in CVD. Females may have cardio-
protective effects due to high levels of estrogen compared to males; however, decrease in plasma 
TG levels in males and SFAs relative abundance in females suggests sex-specific effects of 
SCFAs. I have summarized my findings by proposing a pathway (Figure 4.2) to explain the sex-





               It was also observed that there was no significant difference in the relative abundance of 
hepatic TG species composed of SFAs, MUFAs, n-6 PUFAs or n-3 PUFAs. This indicates that 
SCFAs did not serve as substrate for TG synthesis, or alternately the esterification of fatty acids. 
The endogenous synthesis of TG occurs mainly in liver, adipose tissue and intestine (Rui 2014). 
In this study, the route of administration being intraperitoneal, I expected changes in the fatty acid 
synthesis pathway in liver. I found that SCFAs treatment showed a significant decrease in hepatic 
ACC1 mRNA expression, however, there was no change in hepatic TG species fatty acid 
composition. Interestingly, I found alternations in plasma TG species, suggesting that SCFAs 
might have an effect on the packaging and secretion of lipoproteins (such as VLDL). Lipids 
packaged for release in the blood stream and distribution to peripheral tissues are acted  upon by 
lipases (lipoprotein lipase, hepatic lipase) (Rui 2014); it is likely SCFAs impact lipases, which 

















Figure 4.2 - Proposed pathway showing sex-specific effect of SCFAs on triacylglycerol 
metabolism. It is proposed that a decrease in ACC mRNA expression will lead to a decrease in 
16:0 and 18:0 by reduced activity of elongase. This  may in turn be responsible for a decrease in 
plasma and hepatic TG levels in males, and plasma TG composed of SFAs in females. SCFAs – 
short chain fatty acids, TG – triacylglycerols, SFA – saturated fatty acids, ACC – acetyl CoA-
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4.1.4. Effect of SCFAs on fatty acyl composition of phospholipids   
The positional distribution of fatty acids at the sn-1 and sn-2 positions of the glycerol 
moiety in the structure of PLs is important in metabolic regulation (Beerman C et al., 2005). The 
fatty acid composition of PLs is influenced by processes such as phospholipid degradation and 
phospholipid remodeling. Phospholipases act on PLs to generate lysoPLs, which are potent 
bioactive lipids (Balgoma D, et al., 2010). I used lipidomics analysis to detect plasma and hepatic 
fatty acid composition of PC, LPC, PE, LPE, PS, PI and plasma PA.  
 
4.1.4.1. Effect of SCFAs on PC fatty acid composition 
The primary structure of PC contains C16:0 or C18:0 at the sn-1 position, and C18:1, C18:2 
or C18:3 at the sn-2 position. With the action of enzymes - phospholipase A1 and A2; these 
primary fatty acids are released; the addition of newly synthesized fatty acid/s makes the secondary 
structure of PC. These PC lipid species with two acyl chains are more commonly known as 
diacylated-PC (Beerman C et al., 2005).  
 
4.1.4.1.1. Effect of SCFAs on plasma and hepatic diacylated PC fatty acid composition 
In the current study, SCFA treatment decreased the relative abundance of PC containing 
C16:0 and C16:1 at the sn-2 position, and increased the abundance of n-3 PUFAs such as C22:5 
and C22:6 at the sn-2 position in males (irrespective of C16:0 or C18:0 at the sn-1 position), 
compared to its controls. These findings suggest that SCFAs may have an important role in the 
incorporation of n-3 PUFAs in plasma PC. Similarly, SCFAs increased the relative abundance of 
18:0/22:6 PC in the females compared to its controls, further suggesting a role of SCFAs in 




inflammatory and protect against heart disease (Ratnayake and Galli 2009). Contrary to plasma, 
there was no effect of SCFAs treatment on hepatic PC species composed of SFAs (16:0 or 18:0) 
or PUFAs (18:2, 20:4 or 22:6). A recent study designed to investigate an early onset marker for 
the side-effects of tamoxifen (a breast cancer drug) found that plasma AA (20:4) containing PC 
species was reduced in Sprague-Dawley rats (K. Saito et al. 2017). Thus, alterations in PC fatty 
acyl composition appears to be of significance.  
 
I found that SCFAs treatment reduced the mRNA expression of hepatic ACC1 in males, 
compared to control group. Thus, the decrease in plasma 18:0/16:0 PC could be due to decreased 
fatty acid synthesis in the liver. The increase in 16:0/18:2, 16:0/22:6, 18:0/22:5 and 18:0/22:6 PC 
could be due to the effect of SCFAs on the regulation of elongation and desaturation enzymes. A 
recent study by Chalil A et al. (2018) suggested that an increase in plasma 16:0/22:6 PC levels is 
due to increased PEMT expression, and PEMT activity along with increased FADS protein levels. 
Although no direct comparison can be made with the current study, it would be interesting to look 
into hepatic PEMT and other enzymes involved in PUFA synthesis because SCFAs showed a 
significant increase in plasma PC composed of n-3 PUFAs irrespective of C16:0 or C18:0 in the 
lipid structure.  
 
It was also observed that male control and treatment groups had lower relative abundance 
of plasma and hepatic 18:0/20:4 and 18:0/22:6 PC, compared to female control and treatment 
groups. Moreover, males (both control and treatment groups) had higher abundance of hepatic 
16:0/20:4 PC, compared to female groups. This sex-specific change is similar to a previous report 




(K. Saito et al. 2017). This sex-specific change in plasma and hepatic AA and DHA was suggested 
to be due to a higher expression of liver desaturases in female rats, which replete their DHA status 
more readily than males (Kitson et al. 2012). The increase in 16:0/20:4, and a decrease in 18:0/20:4 
in in this study points towards alterations in the elongation enzymes between males and females.   
 
4.1.4.1.2. Effect of SCFAs on plasma and hepatic LPC fatty acid composition 
LPC is the most abundant lysoPL, generated as a result of the transacylation reaction 
catalyzed by LCAT enzyme, or due to cleavage of ester bond by PLA1 or PLA2 enzymes. LPC 
species composed of SFAs (16:0 and 18:0), MUFAs (18:1), PUFAs (18:2, 20:4 and 22:6) have 
been found in human blood. Studies have confirmed that depending on their specific structure, 
LPCs performs distinct biological roles in metabolism (Rytczak P., Drzazga A., 2013; Kim Y.L., 
Im Y.J., 2017; Rao S.P., Reiderer M., 2013). In the current study, males treated with SCFAs had 
higher relative abundance of hepatic LPC – 16:0e and 18:0p. As discussed above, SCFAs treatment 
caused a decrease in the relative abundance of plasma diacylated PC species composed of SFAs 
(16:0 and 18:0) in males. This suggests a higher conversion of diacylated PC to LPC with the help 
of LCAT or PLA enzyme.  
 
Recent studies have showed that LPCs with saturated acyl chain such as 16:0 LPC 
modulates the immune response; whereas polyunsaturated acyl LPCs, such as 20:4 LPC, and 22:6 
LPC, may have anti-inflammatory action (Hung N.D., Kim M.R., 2009; Jin M.C., Hung N.D., et 
al, 2012). In addition to the involvement of PC species in inflammatory processes; these PLs have 
also been suggested to have beneficial effects in the therapy of Alzheimer’s and Schizophrenia 




and significantly lower levels of plasma LPCs; respectively (Grimm et al. 2011; Orešič et al. 2012). 
LPCs are found to be associated with secretion of enzymes involved with absorption and transport 
of lipids (Drarzga A., 2014). LPC also delivers long chain PUFA, specifically DHA to the brain 
(Grimm et al. 2011). I found that SCFAs caused a higher relative abundance of plasma 18:0/22:5 
and 18:0/22:6 PC, and hepatic 20:4 LPC, suggesting transport of these PC species in the central 
circulation and possibly to the brain.  
 
However, I did not observe any significant change in the relative abundance of brain PC 
composed of n-3 PUFAs (22:5 and 22:6; Appendix figure XX), suggesting that the SCFA mediated 
changes in plasma PC and hepatic LPC profile do not affect brain PC fatty acids. This could be 
because of the short duration of the current study (seven days) to observe an effect on brain fatty 
acids.  
 
There was a significantly lower abundance of plasma and hepatic LPC – 18:0 and higher 
abundance of 18:2 LPC in males (both control and treatment groups), compared to females. Males 
also had a lower relative abundance of plasma and hepatic diacylated 18:0/20:4 and 18:0/22:6 PC, 
compared to females. This suggests that females might tend to retain the PUFAs in PC structure 
while in males, PC species with PUFAs are converted to LPC. 
 
4.1.4.2. Effect of SCFAs on PE fatty acid composition  
PE is generated mainly by the CDP-ethanolamine or PSD pathway in which PS is 
decarboxylated to PE (van der Veen et al. 2017). The biological functions of PE include, autophagy 




for other lipids such as anandamide, glycosylphosphatidylinositol anchors and PC, which helps in 
various signaling pathways (Patel D and Witt S.N., 2017). Similar to PC and LPC, the fatty acyl 
chain/s on the PE and LPE structures have their own distinct biological roles. In addition to PE-
diacylated and LPE, recently PlsPE have been actively researched for their significant contribution 
in membrane fusion and possess oxidants scavenging properties (Moukarzel et al. 2016). However, 
the biological significance of PlsPE composed of varied fatty acyl chains is still poorly understood. 
 
In the current study, SCFAs increased the total abundance of plasma PE-diacylated species 
relative to total PlsPE, which was decreased in plasma. The lipid species responsible for an 
increase of PE-diacylated abundance were – 18:0/18:2, 18:0/20:4 and 16:0/22:6 PE, and those 
species responsible for a decrease of PlsPE were – 18:0p/18:1, 18:0p/20:4, 16:0p/22:6 and 
18:0p/22:6 PE. Furthermore, males did not show any effect of SCFAs on hepatic PE-diacylated or 
PlsPE species; but females showed decreased hepatic PE abundance relative to hepatic PlsPE 
species. These findings indicate that SCFAs modulates plasma PE composition, and the 
alternations in fatty acid composition could attributed to PE biosynthesis in liver in females but 
not in males.  
 
4.1.4.2.1. Effect of SCFAs on plasma and hepatic diacylated PE fatty acid composition 
In the current study, SCFAs caused a significantly higher relative abundance of plasma 
18:0/18:2 and -18:0/20:4 PE in both males and females, compared to their respective controls. 
Interestingly, AA containing PE have been found to have stimulatory role in ferroptotic cell death, 
and has been suggested for treatment of cancer (Kagan V.E., Mao G., 2017). Moreover, SCFAs 




suggesting that SCFAs may have anti-inflammatory effects due to increased incorporation of n-3 
PUFA. Furthermore, SCFAs decreased the abundance of hepatic 18:0/22:5 PE relative to that of 
18:0/22:6 PE in females, compared to its controls. This could be due to a higher conversion of 
DHA from EPA (Kitson et al. 2012), suggesting that SCFAs replete DHA content in PE, similar 
to PC species in SCFA treated females. 
 
Treatment with SCFAs also revealed sex-specific effects where male control and treatment 
groups showed higher relative abundance of hepatic 16:0/18:1 PE, compared to female control and 
treatment groups. This is consistent with another study, where female rats had lower levels of 
hepatic MUFAs (16:1 and 18:1) compared to male rats’ due to higher activity of Δ9 desaturase 
(Rankovic S., Popovic T., 2017).  
 
4.1.4.2.2. Effect of SCFAs on plasma and hepatic PlsPE fatty acid composition 
PlsPE contribute upto 85% of the total PE abundance in mammalian tissues, which is not 
the case with any other vinyl-ether linked PLs. The brain has the highest amount of PlsPE, and 
liver is found to have the least abundance of PlsPE. However, PlsPE acts as reservoir for LC-
PUFAs at its sn-2 position (Moukarzel et al. 2016). In the current study, SCFAs decreased the total 
plasma PlsPE abundance relative to PE-diacylated abundance in both males and females. PE-
diacylated levels have been shown to be tightly regulated  in case of PlsPE deficiency to keep total 
PE and PUFA levels constant (Dorninger et al. 2015) . This group also found that the compensation 
was majorly favored by PE composed of 20:4 and not PE 22:6. I found that SCFAs significantly 
increased plasma and hepatic 18:0/20:4 PE, while plasma and hepatic 18:0p/20:4 and -18:0p/22:6 




The production of both PE-diacylated and PlsPE by Kennedy pathway involves few 
common steps of biosynthesis (van der Veen et al. 2017), for example, in the last step of PE 
biosynthesis pathway, if the CDP-ethanolamine couples to DAG; the end-product is diacylated PE 
whereas coupling to alkylacylglycerol generates PlsPE. This step is regulated by a rate-limiting 
enzyme known as ethanolaminephosphotransferase. The adaptation to maintain total PE levels 
depends on the levels of CDP-ethanolamine generated by CTP: phosphoethanolamine 
cytidyltransferase (ECT) (van der Veen et al. 2017). Findings in this study suggest that SCFAs 
treatment likely modulates hepatic ECT activity in females as there was a significant effect of 
SCFAs on plasma and hepatic PE and PlsPE composition in females, but this was not observed in 
males. 
 
4.1.4.2.3. Effect of SCFAs on plasma and hepatic LPE fatty acid composition 
LPE is not one of the major lyso-glycero phospholipids, and does not have a significant 
biological effect on immune-response, eicosanoid production or transport of PUFAs (Li et al. 
2016).  I found that SCFAs increased plasma 18:0 LPE in males, and decreased hepatic 16:0 and 
18:0 LPE in females compared to the respective controls. A decrease in SFAs containing LPEs 
indicates that SCFAs are likely decreasing the hydrolysis of PE, and there is less conversion of 
PE-diacylated and PlsPE to its lyso form. These findings further suggests that SCFAs may 
downregulate the production of pro-inflammatory eicosanoids, which is induced by palmitic acid 
in lyso PLs (Dennis and Norris 2015). Furthermore, SCFAs may help in maintaining the cell 
integrity and membrane fluidity by maintaining the total PE levels (PE diacylated + PlsPE) by not 





4.1.4.3. Effect of SCFAs on plasma and hepatic PS fatty acid composition  
The biosynthesis of PS involves base-exchange reactions of serine for choline and 
ethanolamine in PC and PE, respectively (Cajka and Fiehn 2014). PC and PE are synthesized by 
the decarboxylation of PS lipid species (D. E. Vance and Vance 2008); thus, the fatty acid 
composition of PS species is  quite similar to PC and PE where the sn-1 position is usually occupied 
with 18:0 and the sn-2 by PUFAs such as 18:2, 20:4 or 22:6. 
 
I found that SCFAs treatment decreased the relative abundance of PS plasma MUFA 
(18:0/18:1), but increased PUFAs (18:0/20:4 and -22:4/22:6) in both males and females, compared 
to its respective controls. Consistent to other lipid classes, males showed no effect of SCFAs 
treatment on hepatic PS composition, while in females, there was a decrease in the relative 
abundance of hepatic 16:0/22:6 and 18:2/22:6 PS, but 18:0/20:4 PS increased. The decrease in 
DHA containing PS species, and an increase in AA containing PS species is unlike the changes in 
PC and PE species that showed an increase in DHA relative to AA. The interconversion of PLs 
due to Land’s cycle (phospholipid remodeling) might be the reason for the differences in fatty acid 
composition of PC, PE and PS (Okuno et al. 2018). This indicates that SCFAs may have effects 
on acyl transferases (such as LPCAT3), which controls the transfer of acyl chains between PLs 
(Rong et al. 2015).  
 
4.1.4.4. Effect of SCFAs on plasma and hepatic PI fatty acid composition 
PI is a membrane lipid that occurs with varied number of phosphate molecules esterified 




(Irvine 2016). These polyphosphoinosities are important lipids involved as transducers of signals 
for cell growth and differentiation (Falkenburger et al. 2010).  
 
 It was interesting to note that the SCFAs treatment of males decreased the abundance of 
plasma PI - 18:0/20:4, relative to 18:0/22:6 PI which was increased, compared to controls. The 
alterations in plasma fatty acyl species suggest an effect of SCFAs on lipoproteins as there was no 
effect of SCFAs on hepatic PI. An increase in the relative abundance of plasma DHA after SCFA 
treatment is consistent with plasma PC and PE, emphasizing that SCFAs likely have anti-
inflammatory effects.  On the other hand, females showed alternations in the hepatic PE, LPE, PS 
and PI species, suggesting changes in the activity of elongase and desaturase enzymes (Kitson, 
Stroud, and Stark 2010). 
 
Males had significantly higher relative abundance of plasma 16:0/20:4 PI, compared to 
females. Females tend to have higher abundance of 20:4 and 22:6 due to increased desaturase 
activity (Kitson et al. 2012). However, an increased level of plasma 16:0/20:4 PI in males indicates 
the effects of SCFAs observed on PI composition is due to the action of phospholipases, and not 
hepatic desaturases (Beerman C et al., 2005). Moreover, it is interesting to observe that PI species 
containing C16:0 at the sn-1 position was higher in males than females, whereas those containing 
C18:0 at the sn-1 position were lower than female groups. These results are consistent with a study 
by Marks et al. (2013)  where they show that female Sprague-Dawley rats have a decreased 
abundance of 16:0, and an increased abundance of 18:0 in liver phospholipids, compared to male 
rats (Marks, Kitson, and Stark 2013). This group suggested that sex-differences are due to an 




4.1.4.5. Effect of SCFAs on plasma PA fatty acid composition 
PA is generated by the phosphorylation of the glycerol moiety and addition of two acyl 
chains during TG biosynthesis. Once formed, the phosphate group at the sn-3 position is esterified 
by an alcohol group (from choline, ethanolamine or serine) to generate PC, PE and PS, respectively 
(van der Veen et al. 2017). Thus, PA acts as the precursor for the biosynthesis of all the other PLs 
(D. E. Vance and Vance 2008). The alternations observed in the fatty acid composition of other 
PLs can be attributed to changes in the PA fatty acid composition. In the current study, SCFAs 
treatment showed a significant decrease in the relative abundance of plasma 16:0/18:1 PA but 
increase in plasma 16:0/18:2, 18:2/18:2, and 18:0/20:4 PA (n-6 PUFAs) in males, compared to its 
controls. On the other hand, females treated with SCFAs only showed a significant decrease in the 
relative abundance of plasma 18:0/18:1 PA, but no effect on PA containing n-6 PUFAs, compared 
to its controls. Considering that PA acts as precursor for synthesis of other PLs, it is possible that 
the decrease in plasma MUFAs in plasma PlsPE and PS could be due to a decrease in plasma PA 
- 18:1 and an increase in 18:2 and 20:4 species in PC, PE and PS lipids, is due to an increase in 
plasma PA - 18:2 and 20:4. This is because PA acts as a precursor for the synthesis of other PLs 
via the CDP-choline/ethanolamine or PSD pathway (Hatch and Choy 2004; D. E. Vance and 
Vance 2008). I have tried to propose the phospholipid remodeling alterations in MUFAs and 








Figure 4.3 Proposed phospholipid remodeling by SCFA treatment. A decrease in PA 
abundance may decrease the abundance of PE and PS, and a decrease in 22:6 PS might relatively 
increase the abundance of PC and PE composed of DHA. PA – phosphatidic acid,  
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In summary, males treated with SCFAs showed a significant decrease in plasma and 
hepatic TC and TG levels, plasma glucose levels, plasma SFAs (18:0/16:0 PC, 18:0p/18:1 PE) and 
MUFAs (18:0/16:1 PC, 18:0/18:1 PS, 18:0/18:1 PA), with a relative increase in the abundance of 
PUFAs (16:0/18:2, 18:0/20:4, 16:0/22:6, 18:0/22:5, 18:0/22:6 - PC; 18:0/18:2, 18:0/20:4, 
16:0/22:6 - PE; 18:0/20:4, 18:0/22:6 - PS; 18:0/22:6 PI; 16:0/18:2, 18:2/18:2, 18:0/20:4 - PA); 
compared to their respective controls. However, there was no effect of SCFAs on the relative 
abundance of hepatic phospholipids except for an increase in 18:1 LPC and a decrease in 18:0/22:6 
PS, compared to respective controls. This indicates that the biosynthesis of LCFAs is not affected 
by SCFAs in males. The changes in plasma lipidomic profile suggests that SCFAs have a 
significant effect on the process of phospholipid remodeling in circulation.  
 
Females treated with SCFAs showed a similar effect on plasma PLs, where MUFAs 
(18:0/18:1 PS, 16:0/18:1 PA) abundance was significantly reduced, relative to an increased 
abundance of PUFAs (18:0/22:6 PC; 18:0/18:2 and 18:0/20:4 PE; 18:0/20:4 and 22:4/22:6 PS), 
compared to its controls. Furthermore, SCFA treated females also showed an effect on hepatic 
PLs, where a significant decrease was observed in the abundance of SFAs (16:0 LPC) and MUFAs 
(18:1 LPC; PE composed of 16:0/18:1, 16:0p/18:1 and 18:0p/18:1), with relative increase in the 
abundance of PUFAs (20:4 LPC; 18:0/20:4 and 18:0/22:6 PE; 18:0/20:4 PS; 18:0/20:4 PI); 
compared to their respective controls. It was also observed that there was decrease in the relative 
abundance of plasma and hepatic PS composed of 22:6 (16:0/22:6, 18:0/22:6, 18:2/22:6 PS), 
hepatic 16:0/20:4 and 16:0/22:6 PI. This suggests that unlike males, SCFAs affect hepatic 




be attributed to changes in hepatic ACC1 which might have an effect on other enzymes involved 
with biosynthesis (SCD, D5D, D6D, ELOVL) and transfer (LCAT, LPCAT) of PUFAs. 
 
Figure 5.1 Proposed pathway for phospholipid metabolism in female rats treated with 
SCFAs. ACC1 – acetyl CoA carboxylase, CDS – cytidine diphosphate synthase, CDP – cytidine 
diphosphate, DAG – diacylglycerol, PA – phosphatidic acid, PC – phosphatidylcholine, PE – 
phosphatidylethanolamine, PI – phosphoinositol, PS – phosphatidylserine, SCD – stearoyl CoA 



























































A diversity in the composition of lipid molecular species is due to remodeling of PUFAs 
into cellular PLs. One of the most researched phospholipid remodeling pathway is the Lands cycle 
which is responsible for changes in membrane composition by the remodeling of AA amongst 
various phospholipids (Hatch and Choy 2004). The Lands cycle involves the action of two enzyme 
classes - acyl CoA synthases and acyl transferases such as LPCAT3/MBOAT5 and 
LPCAT1/MBOAT7 to generate CoA esters of PUFAs, which further incorporates AA into PC and 
PI species (Okuno et al. 2018). In the current study, the increase in hepatic 20:4 LPC could be 
responsible for the increase in the relative abundance of 18:0/20:4 species in hepatic PE and PS, 
and a decrease in hepatic 18:0/20:4 PI, indicating a higher activity of LPCAT3 and a lower activity 
of LPCAT1 in females treated with SCFAs. Enrichment of AA by LPCAT3 in membrane lipids 
have shown an efficient transfer of TG species by reducing the accumulation of TG in hepatocytes 
and enterocytes and promoting clustering of TG in high-density lipoproteins (Hashidate-Yoshida 
et al. 2015).  
In addition to phospholipid remodeling, SCFAs might also have an effect on LCAT and 
lipase enzyme activities in females. This is because females treated with SCFAs showed a 
significant decrease in the abundance of plasma 20:4 ChE relative to hepatic 20:4 LPC; and also, 
showed a decreased SFAs (18:0/16:0/18:0, 18:0/18:0/18:0) in plasma TG species; compared to 
respective controls. Thus, future studies should involve investigating the activity of enzymes 
involved in lipid remodeling, elongation and desaturation. It was also interesting to find that all 
the PLs species containing 18:0 at the sn-1 position increased in abundance, compared to 16:0 at 





It is clearly evident that SCFAs have sex-specific effects on lipid metabolism and the 
lipidomic profile. SCFAs decreased the levels of plasma and hepatic TC, ChE, TG and glucose in 
males, but there was no effect in females, compared to their respective controls. However, females 
showed more prominent effects of SCFAs on plasma and hepatic lipidomics profile. The decreased 
abundance of arachidonyl cholesteryl ester, TG composed of SFAs (18:0 and 16:0) and PLs 
composed of MUFAs (18:1) with relatively increased abundance of PUFAs (20:4 and 22:6) in 
plasma and liver indicates the role of SCFAs in inflammatory processes. Overall, my findings 
suggest that SCFAs have beneficial effects in both sexes; however, the effects may involve 
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Figure I: Plasma ChE PCA output. A) observation chart and B) biplot showing clustering of 
ChE molecular species with SCFA treatments and control. Data were analyzed using multi-variate 
analysis. ChE – cholesteryl ester, MC – male control, MT – male treatment, FC – female control, 

























































































Figure II: Hepatic ChE PCA output. A) observation chart and B) biplot showing clustering of 
the ChE molecular species with SCFA treatments and control. Data were analyzed using multi-
variate analysis. ChE – cholesteryl ester, MC – male control, MT – male treatment, FC – female 
























































































Figure III: Effect of short chain fatty acids on plasma TG composition. A) observation chart 
and B) biplot showing clustering of the TG molecular species with SCFA treatments and control. 
Data were analyzed using multi-variate analysis. TG – triacylglycerols. MC – male control, MT – 



























































































































































































































Figure IV - Effect of short chain fatty acids on the relative abundance of hepatic TG 
composed of: A) n-6 PUFAs B) AA at sn-2 position C) n-3 PUFAs and D) DHA at sn-2 
position. Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test. All 
data are expressed as mean ± SD. Different superscripts indicate significant difference amongst 
groups. P < 0.05 was considered significant (n=6). AA – arachidonic acid, DHA – 









































































































































Figure V: Hepatic TG PCA output. A) observation chart and B) biplot showing clustering of 
TG molecular species with SCFA treatment and control. Data were analyzed using multi-variate 
analysis. TG - triacylglycerols, MC – male control, MT – male treatment, FC – female control, 


























































































Figure VI - Effect of short chain fatty acids on the relative abundance of hepatic TG 
composed of: A) n-6 PUFAs and B) n-3 PUFAs. Data were analyzed using two-way ANOVA 
followed by Tukey’s post hoc test. All data are expressed as mean ± SD. Different superscripts 
indicate significant difference amongst groups. P < 0.05 was considered significant (n=6). TG – 












Figure VII: Plasma PC-diacylated PCA output. A) observation chart and B) biplot showing 
clustering of PC species with SCFA treatment and control. Data were analyzed using multi-
variant analysis. PC – phosphatidylcholine, PCA – principal component analysis, MC – male 



















































































   
  
Figure VIII: Hepatic PC-diacylated PCA output. A) observation chart and B) biplot showing 
clustering of PC molecular species with SCFA treatment and control. Data were analyzed using 
multi-variate analysis. PC – phosphatidylcholine, PCA – principal component analysis, MC – 



































































































Figure IX: Plasma LPC PCA output. A) observation chart and B) biplot showing clustering of 
LPC molecular species with SCFA treatment and control. Data were analyzed using multi-
variate analysis. LPC – lyso phosphatidylcholine, PCA – principal component analysis, MC – 



















































































       
 
Figure X: Hepatic LPC PCA output. A) observation chart and B) biplot showing clustering of 
PC molecular species with SCFA treatment and control. Data were analyzed using multi-variate 
analysis. LPC – lyso phosphatidylcholine, PCA – principal component analysis, MC – male 

























































































            
 
Figure XI: Plasma PE-diacylated PCA output. A) observation chart and B) biplot showing 
clustering of PE molecular species with SCFA treatment and control. Data were analyzed using 
multi-variate analysis. PE – phosphatidylethanolamine, PCA – principal component analysis, 
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Figure XII: Plasma PlsPE PCA output. A) observation chart and B) biplot showing clustering 
of PE plasmalogen molecular species with SCFA treatment and control. Data were analyzed 
using multi-variate analysis. PlsPE – phosphatidylethanolamine plasmalogen, PCA – principal 



















































































         
 
Figure XIII: Hepatic PE-diacylated PCA output. A) observation chart and B) biplot showing 
clustering of PE molecular species with SCFA treatment and control. Data were analyzed using 
multi-variant analysis. PC – phosphatidylethanolamine, MC – male control, MT – male 


























































































Figure XIV: Hepatic PlsPE PCA output. A) observation chart and B) biplot showing 
clustering of PE plasmalogen molecular species with SCFA treatment and control. Data were 
analyzed using multi-variate analysis. PlsPE – phosphatidylethanolamine plasmalogen, PCA – 
principal component analysis, MC – male control, MT – male treatment, FC – female control, FT 









































































            
 
Figure XV: Plasma PI PCA output. A) observation chart and B) biplot showing clustering of 
PI molecular species with SCFA treatment and control. Data were analyzed using multi-variant 
analysis. PI – phosphatidylinositol, PCA – principal component analysis, MC – male control, 


















































































           
 
Figure XVI: Hepatic PI PCA output. A) observation chart and B) biplot showing clustering of 
PI molecular species with SCFA treatment and control. Data were analyzed using multi-variate 
analysis. PI – phosphatidylinositol, MC – male control, MT – male treatment, FC – female 
















































































               
 
Figure XVII: Plasma PS PCA output. A) observation chart and B) biplot showing clustering of 
PS molecular species with SCFA treatment and control. Data were analyzed using multi-variate 
analysis. PS – phosphatidylserine, PCA – principal component analysis, MC – male control, MT 
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Figure XVIII: Hepatic PS PCA output. A) observation chart and B) biplot showing clustering 
of PC molecular species with SCFA treatment and control. Data were analyzed using multi-
variate analysis. PS – phosphatidylserine, PCA – principal component analysis, MC – male 

















































































Figure XIX: Plasma PA PCA output. A) observation chart and B) biplot showing clustering of 
PA molecular species with SCFA treatment and control. Data were analyzed using multi-variate 
analysis. PA – phosphatidic acid, PCA – principal component analysis, MC – male control, MT 




























































































Figure XX – Effect of short chain fatty acids on brain PC with n-3 PUFAs. Data were 
analyzed using two-way ANOVA followed by Tukey’s post hoc test. Data are expressed as mean 
± SD. Different superscripts indicate significant difference amongst groups. P < 0.05 was 
considered significant (n=6). PC – phosphatidylcholine, PUFAs – polyunsaturated fatty acids.  
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